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ABSTRACT OF DISSERTATION 
 
 
NUCLEOTIDE EXCISION REPAIR: IMPACTS OF 
ENVIRONMENTAL CARCINOGENS AND ITS ROLE IN 
CANCER SUSCEPTIBILITY IN APPALACHAIN KENTUCKY 
 
Lung cancer is a particularly devastating disease, accounting for the most deaths 
among all cancer types in the United States.  Despite a reduction in the country’s 
smoking rates, cigarette smoking remains the number one risk factor for lung cancer.  
Additionally arsenic exposure, which occurs primarily through contaminated drinking 
water in the U.S., is associated with increased lung cancer incidence.  The nucleotide 
excision repair (NER) pathway is critical for maintenance of genomic fidelity, removing 
DNA lesions that could otherwise promote DNA mutations and drive carcinogenesis.  
Tobacco smoking introduces significant amounts of DNA damage and produces 
characteristic DNA mutations found in lung cancers of smokers, and arsenic increases 
lung cancer risk in smokers beyond the risk of smoking along.  The contributions of 
these chemicals to DNA damage and cancer have been well documented, but few 
studies have examined their effects on DNA repair pathways, particularly the nucleotide 
excision repair (NER) pathway.  Arsenic, while not directly mutagenic, promotes the 
carcinogenicity of other compounds including agents that produce DNA damage that is 
repaired by the NER pathway.  In this dissertation I investigated the effects of cigarette 
smoke condensate (CSC, a whole-smoke tobacco surrogate) and arsenic on NER.  I 
observed that CSC or arsenic treatment inhibited NER as measured by a slot-blot assay 
using UV-induced photolesions as model substrates to measure NER.  The abundance 
of Xeroderma Pigmentosum complementation group C (XPC), a critical NER protein, 
was significantly reduced in all lines treated with either chemical, while XPA protein was 
unaffected.  CSC and arsenic also affected RNA levels of certain NER genes.  Finally, 
proteasome-regulated XPC turnover was affected by CSC and arsenic treatment, 
suggesting a potential mechanism for XPC protein inhibition.  The observed impairment 
of NER by CSC is critically important in tobacco cancer etiology – CSC introduces DNA 
damage, some of which is repaired exclusively by NER, and CSC inhibits the NER 
pathway as well, providing a two-sided assault on cellular genetic fidelity.  I then 
adapted the NER assay to measure repair in lymphocytes isolated from human subjects 
of a study investigating the high incidence of lung cancer in Appalachian Kentucky.  I 
observed an age-dependent decline in NER efficiency that was modulated by subject 
smoking status and a reduced NER efficiency among current smokers in the lung 
cancer patient population compared to control subjects in the youngest age group, 
suggesting individual DNA repair capacity measured with this repair assay may be a 
biomarker for lung cancer susceptibility. 
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Chapter 1 - Introduction 
1.1 Cancer in the United States 
 Cancer is defined by the National Cancer Institute as a general term for 
diseases in which abnormal cells divide uncontrollably and possess the potential 
to invade nearby tissues or remote locations in the body.  While several genes 
such as K-Ras and p53 are frequently mutated in cancer [1, 2], cancer is not the 
result of a singular genetic defect, but rather cancers arise through a multitude of 
DNA mutations that may be innate or acquired over a lifetime of exposure to 
DNA damaging agents.  Several cellular processes must be altered for a normal 
cell to undergo cellular transformation into a cancer cell, and the types of 
changes required for transformation have been well documented as hallmarks of 
cancer development.  These hallmarks initially included unlimited replicative 
potential, evasion of apoptosis, self-sufficiency with growth factors, resistance to 
growth inhibition, evasion of growth suppression, and angiogenesis [3].  More 
recently, additional hallmarks - avoiding host immune system and deregulating 
cellular energetics - as well as the enabling characteristics of inflammation and 
genomic instability or DNA mutation were added as contributors to the 
pathogenesis of many, if not all, cancers [4].  One of the enabling hallmarks of 
cancer, genomic instability, is a condition of high mutation frequency within the 
genome, and can be the result of DNA repair pathways not functioning properly.  
DNA is under significant pressure to repair the damage it is constantly subject to, 
as failure to do so may lead to an increase in DNA mutation frequency which can 
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promote (i.e. enable) all the cellular changes listed above and thus drive 
carcinogenesis. 
In the United States, cancer is responsible for the second most number of 
deaths among all causes, producing more annual deaths than the next five 
categories combined (http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm 2014 data).  
Only cardiovascular disease ranks higher than cancer.  Cancer is a disease of 
aging - the risk of developing cancer increases in both genders across all sites as 
individuals grow older [5]. The death rate from cancer has increased dramatically 
since the beginning of the last century [6], a result of increased longevity and 
dramatic declines in the conditions that previously produced high levels of 
mortality. From 1900 to 2010, the average U.S. life expectancy increased from 
47.3 to 78.7 years [7] , and during the same period of time cancer went from the 
eighth leading cause of death to the second. In 1900, conditions like pneumonia, 
tuberculosis, and GI infections were the greatest causes of death [6], but these 
conditions have all but been eliminated as causes of death in the United States 
today, contributing to the increase in life expectancy.  Indeed, the death rate 
produced by the top ten leading causes of death has dropped by almost 50% 
between 1900 and 2010. However, cancer and heart disease account for more 
deaths now than over a century ago.  In fact, cancer mortality rates have tripled 
in that time frame [6], and cancer has consistently been the second leading 
cause of death behind heart disease for the last 75 years [8]. Cancer incidence 
and death rates have dropped slightly in recent years from a peak in the early 
1990’s [5], but cancer still remains a significant health risk. 
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Another contribution to the rise of cancer incidence and mortality in the 
U.S. over this time period is that the average age at which individuals are 
diagnosed with cancer across all types is 65 (http://seer.cancer.gov/statfacts/html/all.html).  
This is almost twenty years greater than U.S. life expectancy was at the 
beginning of last century [7].  Since our population is living longer, and since 
cancer rates increase with increasing age, more people now are at risk of 
developing cancer than ever before.  In recent years there has been a stalling of 
life expectancy growth  [9, 10] and a reduction in new cancer diagnoses, but 
there will still be an estimated 1.7 million new cancer diagnoses and about 
600,000 cancer-related deaths in 2016.  Over 14 million people are living with 
cancer in the United States as of 2013 (http://seer.cancer.gov/statfacts/html/all.html).   
1.1.1 Lung Cancer in the U.S. and Kentucky  
 Among the different types of cancer lung cancer produces the highest 
number of deaths in the U.S., three times more than the second leading cause of 
cancer mortality, colon cancer [5].  The five year survival curve for individuals 
diagnosed with lung cancer is 17.7% (2006-2012 data, 
http://seer.cancer.gov/statfacts/html/lungb.html).  This low overall survival is due in part to 
the average stage at diagnosis for lung cancer.  Over half of all lung cancers are 
stage three or worse upon first diagnosis [5].  Five year survival for patients with 
stage three lung cancer is under 5%.  In contrast, stage one lung cancers, while 
only 16% of diagnosed lung cancers, have a five year survival of over 50%.  This 
stresses the importance of early detection in lung cancers.  The fact that lung 
cancers are diagnosed at late stages more frequently than early stages 
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contributes to a chilling statistic.  In the United States, the median age for lung 
cancer diagnoses is 70, and the average age at which those with lung cancer die 
is only 72 (http://seer.cancer.gov/statfacts/html/lungb.html). 
 Lung cancer is responsible for 27.7% of all estimated cancer deaths in the 
United States in 2015 and 34.8% of the estimated cancer-related deaths in 
Kentucky [5].  While the national age-adjusted rate of lung cancer incidence is 
62.74 per 100,000 individuals (based on 2009-2013 data; http://www.cancer-
rates.info/naaccr/), Kentucky’s rate is 50% higher than the national average, with 96.4 
lung and bronchus cancer diagnoses per 100,000 individuals (based on 2009-
2013 data) (Figure 1.1).  Lung cancer is not the only cancer that is causing health 
issues in Kentucky; the state has the highest age adjusted overall cancer 
incidence from 2009-2013 (http://www.cancer-rates.info/naaccr/) (Figure 1.2) and the 
highest over-all cancer death rate among all states [5] 
1.1.2 Smoking and lung cancer in Kentucky 
The primary risk factor in the United States for developing lung cancer is 
cigarette smoking [11].  According to the Centers for Disease Control and 
Prevention, 25.9% of Kentucky adults are current smokers (every day or some 
days) (https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/).  Kentucky’s 
percentage of current smokers was 10% higher than the national average of 
15.1% in 2015 and ranks first among all states for tobacco smoking incidence.  
Tobacco smoking is undoubtedly the principle risk factor for the development of 
lung cancer in Kentucky.  However, within the state there exists a geographical 
disparity of lung cancer incidences. The eastern portion of Kentucky lies within 
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the multi-state region of the United States called Appalachia.  In Kentucky, the 
Appalachian region has a higher lung cancer incidence than in the rest of the 
state (http://cancer-rates.info/ky/index.php), likely due to the high rate of tobacco use, 
which is greater than the rate in non-Appalachian Kentucky [12] and 60-80% 
higher than the national average.  When viewed on a county-by-county basis, the 
high lung cancer incidence counties cluster in the eastern portion of the state, the 
Appalachian region (Figure 1.2a).  By dividing the state into “Non-Appalachia” 
and “Appalachia” counties, it becomes clear that average lung cancer incidence 
of counties in the Appalachian region is over 20% higher than of those in the 
non-Appalachian region (Figure 1.2b).  Within the greater Appalachian region of 
the U.S., a higher cancer burden is observed across all sites compared to non-
Appalachian areas in the United States, particularly with regard to tobacco-
related cancers [13].   
While lung cancer rates in Appalachian Kentucky are primarily a result of 
tobacco smoking rates that are over 50% higher than the national average and 
greater than the rates in the rest of the state [12], there are clusters of counties in 
Kentucky with lung cancer rates that are higher than the rest of the state after 
controlling for gender, age, and smoking status [14], suggesting that additional 
factors may be contributing to the high lung cancer incidence (Figure 1.3).  Two 
of the three high lung cancer incidence clusters reside within Appalachian 
Kentucky, while a third cluster contains many counties that reside within a large 
metropolitan area and lung cancer rates may be high as a result of increased 
pollution associated with such a region. Additionally, a multi-state study of 
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Appalachian United States found that the increased lung cancer rates in coal 
mining areas within the region could not be explained by tobacco use alone [15], 
and the high lung cancer incidence clusters in Appalachian Kentucky are also 
areas of high coal production [14].  These studies open the possibility that some 
as yet undetermined factors are contributing to increased lung cancer incidence 
in Appalachian Kentucky and perhaps the greater Appalachian region.    
1.2 DNA Repair 
 DNA is a highly reactive, massively large molecule (a single human diploid 
cell contains almost seven billion nucleotides) that cannot be replaced if 
damaged. Instead, DNA must be repaired in response to the persistent damage it 
is subject to, or otherwise the damage may become permanent, which is the 
definition of a DNA mutation.  There are several types of DNA damaging agents 
including exogenous agents (such as UV light and tobacco smoke) and 
endogenous byproducts of normal cellular metabolism.  DNA can also undergo 
spontaneous nucleotide hydrolysis (producing abasic sites) and spontaneous 
deamination (which can produce base changes) [16, 17].  The reactivity of DNA 
is due in large part to the unsaturated ring structure of the DNA bases, producing 
a nucleophilic environment subject to reactions with electrophiles [18].  
Additionally, the negatively charged phosphodiester backbone attracts positively 
charged ions capable of reacting with DNA, including metal ions that can 
undergo proximal redox cycles (Fenton chemistry) to generate reactive oxygen 
species.  The typical result of DNA damage is a local disruption of standard 
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duplex structure, which forms the basis for recognition by DNA repair proteins 
across multiple DNA repair pathways. 
Humans possess three highly efficient DNA excision-repair pathways to 
preserve genomic integrity.  These pathways are nucleotide excision repair 
(NER), base excision repair (BER), and mismatch repair (MMR), and they are 
genetically conserved processes in eukaryotes whose disruptions often lead to 
increased genomic instability and ultimately increased cancer incidence.  In 
addition to these, there are pathways involved in repairing double-strand breaks, 
a type of damage that excision repair cannot address as a suitable template does 
not exist.  All of these processes are necessary to ensure proper genomic 
maintenance and cellular survival.   
The excision repair pathways are discussed in more detail below.  
Combined they respond to the majority of DNA damage cells face from 
exogenous and endogenous sources.  It should be noted that while all three 
pathways are critical and none can be fully complemented by the other two, NER 
is the sole focus of my dissertation.  The experiments laid out herein involve 
environmental factors that may promote carcinogenesis by producing lesions 
recognized by NER, interfering with normal NER function, or both.  While all 
three excision repair pathways are important for preventing DNA mutations that 
can promote carcinogenesis as I will describe below, the MMR and BER 
pathways were not the subjects of our research, and are included here to 
highlight the fact that mutations and polymorphisms in genes involved in all three 
excision repair pathways can increase cancer risk. 
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1.2.1 NER 
 NER is a versatile pathway that removes a wide variety of structurally 
diverse DNA lesions including those generated by metabolites of chemical 
carcinogens such as polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke 
as well as cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-
4PPs) induced by exposure to UV light [19]. In mammals, at least 20 different 
protein factors participate in NER, including the XPA-G factors that are singly 
defective in the 7 corresponding complementation groups of the human disease 
Xeroderma Pigmentosum (XP).  NER efficiency is also regulated by the tumor 
suppressor factor p53 through transcriptional regulation of the XPC and DDB2 
gene products in response to DNA damage [20-23]. The NER pathway, also 
referred to as global genome nucleotide excision repair (GG-NER), is responsible 
for removing DNA damage from nontranscribed DNA. Damaged present in the 
transcribed strands of active genes are removed by transcription-coupled 
nucleotide excision repair (TC-NER) [24].  
The following is an abridged explanation of the steps in the NER pathway 
(reviewed quite well in [19, 25]).  The NER pathway is initiated when a helically 
distorting DNA adduct forms (Figure 1.4A).  The manner of recognition is 
different between two sub-pathways.  In GG-NER the DNA recognition protein is 
XPC [26].  In order to be able to respond to the multitude of DNA adducts that 
are substrates for NER, XPC, stabilized by its obligate binding partner HR23B, 
recognizes the helical distortion in DNA produced by an adduct [27] and binds to 
the undamaged strand opposite the lesion (Figure 1.4B).  Recent evidence 
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suggests that the rate limiting step in NER is the efficiency with which DNA 
damage can be recognized, implicating XPC as the rate limiting enzyme in GG-
NER [28-30].  As TC-NER functions exclusively on the transcribed strand of 
actively transcribed DNA, damage recognition during TC-NER is initiated when 
the RNA polymerase II complex is stalled by the DNA adduct, which stabilizes 
the CBS protein that is present in the complex and promotes recruitment of the 
subsequent NER machinery by CSB [24, 31, 32]. 
After damage recognition, the two pathways converge for the remainder of 
the repair process. Damage recognition proteins (XPC in GG-NER and CSB in 
TC-NER) recruit the TFIIH transcriptional complex containing the helicases XPB 
and XPD to the site of the damage.  XPB pries open the DNA and permits XPD 
to travel across the damaged strand, unwinding DNA until it stalls at the 
damaged nucleotide (Figure 1.4C) [33, 34].  The unwinding permits subsequent 
NER factors access to the DNA damage site, including the endonuclease XPG 
(which is recruited through interactions with TFIIH), the single strand binding 
protein RPA, and XPA (Figure 1.4D).  XPA is an indispensable component of the 
NER pathway, but the role it plays is still somewhat vague.  XPA can interact with 
a multitude of NER factors including XPC, THIIH, RPA, XPF/ERCC1, and more.  
It may serve to verify that all necessary factors are in place ahead of the DNA 
incision step.   The other directional endonuclease complex, XPF/ERCC1, is 
recruited to the damage site through interactions with XPA [35]. After recruitment 
of the XPF/ERCC1 complex, it cuts 5’ of the damaged nucleotide (Figure 1.4E)  
This 5’ incision produces a 3’ OH group that serves as a template on which a 
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polymerase can bind and begin synthesis of DNA to replace the damaged strand.  
After synthesis has begun, XPG performs the second single-stranded cut 3’ of 
the damaged site, releasing the damage-containing oligonucleotide (Figure 
1.4F).  The original integrity of the DNA is restored when the repair polymerase 
synthesizes an approximately 30 nucleotide segment of DNA and a DNA ligase 
seals the strand (Figure 1.4G) [36].  A recent investigation into the post-incision 
steps in NER reveals that the process is more complicated than previously 
thought.  While DNA polymerases δ and ε were initially thought to be the 
principle polymerases in the gap filling step, the error prone polymerase κ also 
plays a role in repair synthesis [37]. Further complicating the post-incision 
process, the ligase used to seal the nicked DNA after repair synthesis can be 
either DNA ligase I or IIIα, and which one is used may depend on the replicative 
status of the cell [38].   
 There are three primary inherited disorders resulting from mutations in 
NER genes in humans; xeroderma pigmentosum (XP), Cockayne syndrome 
(CS), and trichothiodystrophy (TTD) [39], although there are additional 
syndromes stemming from NER deficiencies, depending on the functional 
consequences of mutation in the repair protein  [40, 41].  Of the primary 
disorders, XP is characterized by extreme photosensitivity and a dramatically 
elevated incidence of skin cancer, as well as an increased internal cancer 
mortality [40].  The average age at diagnosis of nonmelanoma skin cancer for 
individuals with XP is 50 years sooner than the general population [40, 42].   
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While the disorder is rare (as infrequent as an estimated 1 in 1,000,000 in 
the U.S.), there are regions in the world where XP frequency is considerably 
higher. In Japan, for example, the frequency of XP-A in the general population is 
about 1 in 22,000 [43].  This high incidence also produces a carrier frequency of 
XP-A in Japan that is thought to be as high as 1 in 100.  The carriers of XP-A do 
not exhibit repair deficiencies, as measured by an unscheduled DNA synthesis 
(UDS) assay [44], nor do XP-A heterozygote mice show any increased incidence 
of tumor development compared to wildtype mice following UV exposure [45].  
However, there is some evidence to suggest that other XP heterozygotes may 
have an intermediate repair phenotype.  XP-C heterozygotes have reduced XPC 
RNA levels compared to genotypically normal individuals [46], and reduced 
expression of XPC has been associated with increased risk for developing 
certain head and neck cancers [47], suggesting that certain XP carriers may be 
at an increased risk for cancer development. 
Polymorphisms in NER genes have also been explored for their potential to 
contribute to cancer risk, which will be discussed in more detail in Chapter 5.  
Exploring the health consequences of NER gene heterozygosity or NER gene 
polymorphisms is part of a process of determining whether these variations exist 
in a population and can be used as biomarkers to predict cancer risk for 
individuals who may have suboptimal function of their nucleotide excision repair 
pathway. 
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1.2.2 MMR 
 The MMR pathway in eukaryotes is responsible for a 50-100 fold increase 
in DNA fidelity [48] by identifying single base mismatches or small 
insertions/deletions that result from improper DNA replication.  The pathway is 
remarkably similar across eukaryotes and prokaryotes, although it is modified in 
E. coli.  In bacteria, a homodimer of the MutS protein recognizes mismatched 
bases or small insertions/deletions [48].  This process is similar in eukaryotes, 
with three MutS homologs (MSH2, MSH3, and MSH6) forming the heterodimeric 
complexes MutSα (MSH2/MSH6) and MutSβ (MSH2/MSH3). MutSα recognizes 
single base mismatches and small insertion/deletion loops (IDLs) while MutSβ 
recognizes larger IDLs [49]. 
After recognition of the mismatch/IDL, a homodimer of the MutL protein is 
recruited in bacteria to nick the nascent strand near the site of the mismatch.  In 
eukaryotes, three heterodimer MutL homologs , MutLα, MutLβ, and MutLγ are 
formed by complexing MLH1 with PMS2, PMS1, and MLH3 respectively [50].  Of 
these, MutLα is believed to be responsible for the majority of MMR in eukaryotes 
[51].  Upon strand incision, an exonuclease (EXO1/UvrD in 
eukaryotes/prokaryotes) is recruited to remove the strand with the replicative 
error, a polymerase (Polδ/Pol III) fills in the gap, and a ligase seals the nick, 
completing the repair process. 
Human homologs of the bacterial MutL/S proteins are mutated in a 
number of cancers, including cancers arising from Lynch syndrome, an inherited 
cancer syndrome resulting from a germline mutation in one of the MMR genes 
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[52], primarily the MLH1 or MSH2 genes.  This is not surprising given MSH2 is 
present in both MutS complexes, and MLH1 is present in all three MutL 
complexes, and thus losing either of these proteins abolishes that component of 
the MMR pathway entirely.  The inherited mutation occurs in only one allele of 
the MMR gene, so a second somatic mutation is required, which is why the 
disorder manifests later in life, as opposed to the inherited NER disease XP.   
Only about 5% of colorectal cancers are a result of Lynch syndrome, but the 
disease also contributes to other cancers including endometrial, ovarian, and 
stomach cancers.  Of all hereditary nonpolyposis colon cancers, upwards of 90% 
are a result of a mutation or epigenetic silencing of a MMR gene [53].  There is 
also mounting evidence that, similar to what has been reported with NER genes, 
polymorphisms in MMR genes may also contribute to increased cancer risk [54-
56] 
1.2.3 BER 
 The BER pathway is responsible for detecting and eliminating a variety of 
DNA lesions targeted specifically to the purine and pyrimidine bases that 
compose the inner portion of the DNA complex.  Lesion recognition in the BER 
pathway is achieved through a number of glycosylases which recognize specific 
base modifications or abnormal base pairings.  After recognition, the glycosylase 
removes the modified base by cleavage of the N-glyosidic bond, but leaves the 
sugar moiety intact, producing an abasic site (often referred to as an AP site for 
apurinic/apyrimidinic).  The presence of an AP site recruits APE-1 (AP 
endonuclease 1) to cut the sugar-phosphate backbone at the abasic site’s 5’ end, 
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producing a 3’ hydroxyl site.  Once the DNA backbone is cleaved, DNA Pol β can 
use the 3’ hydroxyl to resynthesize the missing nucleotide.  Cleavage of the extra 
phosphate group (also by Pol β) and ligation of the DNA backbone (XRCC-
1/DNA ligase IV) finish the repair process.  When only one nucleotide is removed 
in this fashion, as is generally the case, the repair pathway is referred to as “short 
patch BER.”  Occasionally more nucleotides than the one recognized by the 
glycosylase are removed in a process known as “long patch BER.”   
Germline mutations in various glycosylases involved in BER have been 
associated with increased cancer risk.  A homozygous mutation in the NTHL1 
glycosylase is associated with increased colorectal cancer [57].  A compound 
heterozygous mutation of the glycosylase MYH, the human homolog of bacterial 
mutY, has been attributed to an inherited cancer disorder MAP (MUTYH 
associated polyposis) [58, 59].  
BER proteins downstream of the glycosylase are not traditionally 
inactivated in human cancers.  The remaining components of the core BER 
pathway (APE-1, Pol-β, FEN1, and DNA-ligase) are critical for life – knocking 
them out causes embryonic lethality [60], and as such a cell acquiring a mutation 
that inhibits any of these proteins is much more likely to die than to undergo 
carcinogenesis.  However, there is considerable evidence that polymorphisms in 
certain BER genes modulate cancer predisposition.  Abnormal estrogen 
metabolism can lead to an accumulation of depurinating adducts, leading to 
formation of AP sites [61].  Variation in BER efficacy due to genetic 
polymorphisms may affect the repair of these AP sites and perhaps contribute to 
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an increase in mutagenesis and ultimately breast cancer risk [62].  Multiple APE-
1 polymorphisms have been associated with increased breast cancer 
development [63].   
1.2.4 Concluding remarks on DNA repair 
 As I have described above, all three excision repair pathways - NER, 
MMR, and BER - are vital for maintenance of genomic fidelity.  A failure in any of 
these pathways can lead to corruption of the genetic code through induction of 
DNA mutations, producing an increase in cancer risk.  There are several ways in 
which a repair pathway’s efficiency can be reduced.  Polymorphisms producing 
semi-functional proteins can have negative effects on repair efficiency, as can 
expression level variations like those seen in some heterozygotes, or those seen 
when transcript levels of a repair gene are reduced.  Variations expression of 
repair proteins and polymorphisms in repair genes can and have been measured 
in general populations as indicators of individual relative risk of developing 
various types of cancers, which will be discussed in more detail in chapters 5 and 
6.  By their nature, expression studies and polymorphism studies are limited to 
the genes/proteins of interest.  Repair pathways, NER in particular, employ 
dozens of proteins to respond to DNA damage, and even more proteins are 
involved in regulating repair protein stability through post-translational 
modifications and expression levels through transcription regulation.  As a result, 
these experiments may not measure all the factors that contribute to an effective 
repair pathway’s performance.  Instead, an assay that measures the functional 
efficiency of a repair pathway would be a more effective indicator of individual 
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variations in repair efficiency and may be the most useful measure of an 
individual’s cancer development risk. 
1.3 Tobacco smoking and DNA damage 
 It has been over 50 years since the initial publication of the Surgeon 
General’s first report on the health consequences of cigarette smoking with an 
emphasis on lung cancer, and since that reporting tobacco smoking rates have 
been on the decline in the United States [11].  While adult smoking rates are 
down from over 40% when the report was published to about 15% today, tobacco 
use continues to be a considerable health hazard in the United States, with an 
estimated 36.5 million people still smoking in 2015 [64].  Tobacco smoking 
remains the number one risk factor for lung cancer development despite the drop 
in rates, with smoking contributing to approximately 80-90% of lung cancers [11]. 
Tobacco smoke contains over 70 known human carcinogens [65, 66] including a 
number of polycyclic aromatic hydrocarbons (PAH) [67]. Perhaps the most well 
researched of the PAH chemicals in tobacco smoke is benzo[a]pyrene (B[a]P).  
Through a three stage process involving cytochrome p450s (usually CYP1A1 or 
CYP1B1) and microsomal epoxide hydrolase, B[a]P is metabolized by into one of 
many isoforms of benzo[a]pyrene-7-8,dihydrodiol-9,10-epoxide (BPDE) [68, 69]. 
BPDE is a DNA reactive compound that covalently binds to guanines at the N2 
position [70-72] and causes predominantly G to T transversion mutations if left 
unrepaired [73].  While the BPDE adduct is a substrate for the nucleotide 
excision repair pathway [74, 75], failure to remove the adduct leads to increased 
mutation formation which drives carcinogenesis. 
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The relationship between NER and B[a]P mutagenesis is dependent on a 
cellular response that occurs when NER fails to remove the adduct. When NER 
is unable to process the lesion before DNA replication occurs, a low fidelity 
lesion-bypass polymerase is recruited to synthesize DNA across from the 
adducted guanine [76].  In yeast, the bypass polymerase is able to correctly 
insert cytosine about 75% of the time, but 14% of all insertions across from (+)-
trans-anti-BPDE-N2-dG, the predominant stereoisomer of BPDE [71], were 
adenine [76].  This mismatch, upon another round of replication, would produce a 
G-T transversion mutation in one of the daughter cells.  An increase in DNA 
damage burden or a decrease in NER function could result in an increased 
persistence of the DNA adduct, increasing the need for the lower fidelity 
replicative polymerase and thereby increasing the rate of mutation formations.   
The significance of this one carcinogen out of the scores present in 
tobacco smoke can be seen in the mutational signature of the p53 gene in lung 
cancers from tobacco smokers.  The tumor suppressor gene p53 is mutated in 
around 60% of human lung cancers [77].  BPDE adducts produce mutational 
hotspots in P53 in vitro that are at the same major codons mutated in human 
lung cancers (including codons 157, 158, 245, 248, and 273) [78, 79], suggesting 
that P53 mutations observed in lung cancers are produced at least in part by 
unrepaired BPDE adducts.  Our current understanding as to why BPDE lesions 
are found at these hotspots relates to the presence of CpG islands in the P53 
gene.  It has been observed that p53 is methylated at all CpG dinucleotides 
within the exon 5-8 coding region, the same location of the mutational hotspots 
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mentioned above [80]. These methylated CpGs are preferential targets for BPDE 
adduct formation [81], providing further evidence that connects tobacco smoking, 
via BPDE adduct generation, to the P53 mutational spectra observed in lung 
cancers of smokers.  Therefore, the relationship between tobacco smoking and 
lung cancer involves DNA damage produced by tobacco smoke that the NER 
pathway has not repaired, resulting in damage tolerance mechanisms of certain 
lesion bypass polymerases that increase the potential for mutagenesis.  
1.4 Another factor for lung cancer in Kentucky - Arsenic 
 There are of course many more risk factors for the development of lung 
cancer.  One such risk factor is arsenic exposure, which is associated with 
increases in cancer risk at several organ sites, including the lung [82, 83].  The 
relationship between arsenic exposure and cancer risk will be discussed in 
greater detail in chapter 4.  In the United States there are several routes of 
arsenic exposure, including contaminated drinking water, occupational exposure, 
and even as a component in tobacco smoke.  Arsenic exposure increases the 
risk for developing lung cancer, among many others.  Interestingly, arsenic is not 
a direct mutagen [84], and the mechanism most commonly proposed for its 
carcinogenicity is a co-carcinogenic function, increasing the carcinogenic 
potential of other agents.   
 As mentioned above, there is an increased incidence of lung cancer in 
Appalachian Kentucky relative to the rest of the state that cannot be fully 
explained by a higher incidence smoking.  There are many possible explanations 
for this disparity.  The high incidence could be a consequence of higher smoking 
19 
 
quantity (the amount the smokers in the region smoke), exposure to other cancer 
causing agents such as radon or heavy metals, a genetic predisposition to 
cancer development that is over-represented in the region, or some combination 
of these and other factors.  One possible explanation for the increased incidence 
could be related to arsenic exposure in the region.  High levels of arsenic have 
been observed in well waters central Appalachia, including Eastern Kentucky 
[85], as well as in shale outcroppings in the region [86].  Appalachian Kentucky 
contains high levels of arsenic found in coal deposits [87-89].  A process of coal 
mining in the region known as mountaintop removal may introduce arsenic into 
local water systems [90]. This arsenic could find its way into unregulated private 
water wells, which has the potential to produce locally high arsenic exposure.  
Indeed, areas in which coal mining has been associated with high incidence of 
lung cancer include the greater Appalachian region [15] as well as a 
southeastern region of Kentucky within Appalachia [14], suggesting that arsenic, 
or some other component of Appalachian coal, may contribute to lung cancer 
rates in the region. 
 Mechanistically, several hypotheses have been put forth to explain arsenic 
carcinogenesis including inhibition of DNA repair pathways, promoting the 
carcinogenesis of other compounds, and this will be discussed in greater extent 
in chapter 4.  As tobacco smoke is the greatest risk factor in lung cancer 
development, and since it is well established that tobacco smoke generates DNA 
damage repaired by NER that contributes to lung cancer risk in smokers, if 
arsenic was able to inhibit of the repair of tobacco smoke-induced DNA damage 
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(via an inhibition of the NER pathway), that would exacerbate the damage, 
increase its mutagenic potential, and ultimately increase lung cancer risk. 
1.5 Research Hypothesis 
My research centers on the impact of environmental factors on the 
nucleotide excision repair pathway and the consequences of variations in NER 
efficiency with regards to cancer risk, particularly lung cancer risk in Appalachian 
Kentucky.  Tobacco smoking is undoubtedly the primary factor in the 
development of lung cancer.  Tobacco smoke produces DNA damage that is 
eliminated by the nucleotide excision repair pathway.  A reduction in the 
efficiency of the NER pathway could result in a reduction in the repair of DNA 
damage caused by tobacco smoke and an increase in the risk of developing lung 
cancer.  Based on those observations, I propose that tobacco smoke 
condensate, used as a surrogate for whole tobacco smoke, inhibits NER 
function, which may be an additional mechanism through which it promotes 
carcinogenesis.  Chapter 3 will address this hypothesis using lung cells in a cell 
culture model.  As mentioned above, another lung carcinogen, arsenic, increases 
the carcinogenicity of other DNA damaging agents. I propose that arsenic inhibits 
NER function, which may be one mechanism of the carcinogenesis of arsenic.  
Chapter 4 will address this hypothesis using lung and skin cells in a cell culture 
model   
The results of the cell culture studies coupled with the high lung cancer 
incidence in eastern Kentucky prompted an epidemiological study to address the 
following hypothesis: the increased lung cancer incidence in Appalachian 
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Kentucky is due in part to an impaired NER efficiency of individuals in the region, 
which may be a consequence of environmental exposure from agents such as 
tobacco smoke and arsenic.  In other words, we hypothesize that individuals with 
lung cancer in Appalachian Kentucky have reduced NER efficiency relative to 
individuals without lung cancer in the region.  To address this hypothesis, a DNA 
repair assay was adapted to measure the efficiency of NER in a human 
population, and the process of confirming the reliability of this assay is presented 
in chapter 5, along with the effect of experimental variables on the measurement 
of NER efficiency in the study population.  Chapter 6 focuses on the population 
demographic factors that impacted the measurement of the efficiency of NER in 
a study population.  Lastly, in chapter 7 I address unanswered questions from the 
previous chapters, and I present the findings of a comparison of the efficiency of 
NER between lung cancer cases and healthy controls. Additionally, I discuss how 
this study will help establish guidelines for proper case-control comparisons 
using the NER repair assay in the future. 
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Figure 1.1 Lung cancer and total cancer incidence in the United States. 
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Figure 1.1. Lung cancer and total cancer incidence in the United States.  (A) 
Map of lung cancer incidence in the United States.  Lung cancer rates for each of 
the 50 states are shown.  Dark red states indicate a high incidence of lung 
cancer.  Kentucky has the highest age-adjusted incidence of lung cancer in the 
country at 96.41 cases per 100,000 people, over 50% higher than the national 
average of 62.74.  (B) Map of cancer incidence in the United States.  Aggregate 
cancer rates at all sites for each of the 50 states are shown.  Dark red states 
indicate a high incidence of lung cancer.  Kentucky has the highest age-adjusted 
incidence of cancer at all sites in the country at 520.88 cases per 100,000 
people, compared to the national average of 457.  Data is from 2009-2013, and 
is from the NAACCR (http://www.cancer-rates.info/naaccr/)  
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Figure 1.2 Variation in lung cancer frequency within Kentucky.  
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Figure 1.2. Variation in lung cancer frequency within Kentucky.  (A) Lung 
cancer rates for each of the 120 counties within Kentucky are shown.  Dark red 
counties indicate a high incidence of lung cancer.  The high incidence counties 
are present throughout the state but are at the greatest density in the far-eastern 
region, the area known as Appalachia. (B) A breakdown of cancer incidence in 
Kentucky between counties designated as Appalachian or non-Appalachian 
shows the burden of lung cancer is considerably higher (by about 20%) in 
Appalachian Kentucky as compared with the rest of the state. 
  
26 
 
Figure 1.3. Clusters of high lung cancer incidence in Kentucky.   
 
 
Figure 1.3. Clusters of high lung cancer incidence in Kentucky.  Lung cancer 
rates cannot be explained by smoking incidence in certain regions of Kentucky.  
Using a spatial scanning statistic that groups together counties in an expanding 
radius from a central point, Christian et al. 2011 discovered three clusters of 
counties in Kentucky whose average lung cancer rate was higher than the state 
average after correcting for smoking, age and gender.  Two of these clusters 
(clusters 1 and 2) lie within Appalachian Kentucky. 
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Figure 1.4. Steps in the Global Genomic Nucleotide Excision Repair  
(GG-NER) pathway.  
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Figure 1.4. Steps in the Global Genomic Nucleotide Excision Repair  
(GG-NER) pathway.  (A) A bulky, helically distorting DNA adduct forms. (B) DNA 
damage recognition protein XPC, complexed with its binding partner HR-23B recognizes 
the distortion in DNA caused by the adduct and binds on the undamaged strand 
opposite the adduct. (C) Binding of XPC promotes recruitment of the TFIIH complex, 
which uses dual helicases (XPB and XPD) to unwind the DNA, forming a single stranded 
bubble.  (D) Opening of the DNA promotes recruitment of several proteins the complex, 
including the endonuclease XPG, the single-strand DNA binding protein RPA, and XPA, 
which functions to confirm the presence of all the components necessary to perform 
subsequent steps.  (E)  ERCC1-XPF endonuclease is recruited to the damage site and it 
cuts 5’ to the DNA adduct on the damaged strand.  (F) After the 5’ incision a DNA 
polymerase (normally delta or epsilon) is recruited to the site along with RFC and PCNA 
to resynthesize the gap produced by the endonucleases.  XPG then cuts 3’ of the 
damage site, releasing the single stranded oligonucleotide containing the damage site. 
(G)  The sugar-phosphate backbone is sealed by DNA ligase I or III to complete the 
repair process.  
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Chapter 2 - Experimental Methods 
2.1 Cell Culture 
The human lung fibroblast cell line IMR-90 (obtained from the American 
Type Culture Collection) was grown in minimal essential medium (Eagle) 
containing Earle’s salts (Mediatech) supplemented with 0.1 mM non-essential 
amino acids (Lonza), 2 mM glutamine (Mediatech), 100 units/ml penicillin, 100 
µg/ml streptomycin and 10% fetal bovine serum (Sigma).  
The human bronchial epithelial cell line, BEAS-2B (obtained from the 
American Type Culture Collection), was grown in Dulbecco’s Modified Eagle’s 
Medium supplemented with 2 mM glutamine, 100 units/mL penicillin, 100 µg/mL 
streptomycin and 10% heat inactivated fetal bovine serum.   
Cultures of primary mouse keratinocyte cells were isolated as described 
[91].  Briefly, cells were taken from the epidermis of newborn C57BL/6J mice 1-3 
days after birth and grown in keratinocyte growth media composed of an equal 
volume of low calcium (LoCal) media containing (MEM Eagle with Earle’s salt, 
without calcium, 8% chelexed FBS, 2 mM glutamine, 100 units/mL penicillin, 100 
µg/mL streptomycin, 0.25 µg/mL fungizone and 0.06 mM CaCl2 and fibroblast 
conditioned LoCal medium. In order to condition the LoCal medium, primary 
mouse fibroblast cells were grown in it until confluent, and the medium was 
removed, filter sterilized with a 0.22 micron filter, and stored in minus 80°C until 
use.  All cell lines were maintained in a 5% CO2 incubator at 37ºC. 
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2.2 Preparation of CSC  
Cigarette smoke condensate (CSC) was prepared using the University of 
Kentucky Reference 3R4F Cigarettes as previously described (Hsu et al 1991).  
Briefly, the particulate phase of smoke was collected on Cambridge filters using a 
30-port smoking machine (Borgwaldt) under standard Federal Trade Commission 
conditions, [92]  dissolved in DMSO at a concentration of 40 µg/µl, and stored in 
small aliquots at -80oC.  At the time of use, aliquots were thawed in a 37°C water 
bath and discarded after use. 
2.3 Treatment of cells with CSC  
IMR-90 cells were grown to confluency prior to treatment and then treated 
with CSC for 24 h unless otherwise stated.  BEAS-2B cells were seeded at a 
density of 1.2 million cells per 10 cm plate, allowed to grow for 24 h and log 
phase cells were then treated with CSC for 16 h. The growth of BEAS-2B cells 
does not exhibit contact inhibition so studies could not be performed using 
confluent cultures.  For both cell lines, control (mock treated) cells were treated 
with DMSO, the solvent used for the preparation of CSC, at a volume equal to 
that used for the highest dose of CSC in each experiment.   
2.4 Treatment of cells with sodium arsenite 
IMR-90 and mouse keratinocyte cells were grown to confluency and then 
treated with arsenite for 24 h unless otherwise stated.  Control (untreated) cells 
were treated by adding comparable volumes of water, the solvent used to 
dissolve sodium arsenite, to the medium.  In the repair assays, sodium arsenite 
was added to the medium for the duration of the repair interval. 
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2.5 Treatment of cells with MG-132 
MG-132, a potent inhibitor of proteasome mediated proteolysis, was 
prepared from a 2mM stock solution from EMD Bioscience (catalog # 475791) 
stored at -20ºC.  The solution was thawed immediately prior to treatment and 
diluted for use.  To investigate how changes in the abundance of XPC protein are 
influenced by UV-C irradiation, confluent IMR-90 cells were treated with MG-132 
for 4 h prior to irradiation.  The cells were irradiated with 20 J/m2 UV-C and either 
lysed immediately or returned to medium containing MG-132 for incubation after 
UV.  XPC levels were examined using the Western method described above. To 
investigate a potential involvement of the proteasome in the turnover of XPC 
after cells are treated with CSC or arsenite, confluent IMR-90 cells were treated 
with the indicated concentrations of CSC or arsenite for 16 h in the presence or 
absence of MG-132.  After treatment, cells were counted and lysed, and XPC 
levels were measured by Western Blotting. 
2.6 Analysis of cell viability for CSC and arsenite treatments 
Cultured cells were grown and treated with CSC or arsenic as described 
above. After the appropriate treatment duration, cells were trypsinized, washed 
with chilled PBS, centrifuged, and resuspended in 10 mL of chilled PBS. Cells 
were counted in triplicate (at minimum) for each dose using trypan blue dye 
exclusion.  
2.7 Isolation and cryopreservation of peripheral blood mononuclear cells 
PBMCs were isolated from blood samples using standard Ficoll density 
gradient centrifugation methods [93].  Upon receipt, the blood was warmed to 
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room temperature, diluted 1:1 in serum-containing medium, (90% RPMI, 10% 
FBS) and layered onto the density gradient.  The samples were centrifuged in an 
Allegra X-22R centrifuge (400g, 25ºC, 30 m), and the PBMC cell layer (buffy 
coat) was extracted and washed in serum containing medium.  The cells were 
counted, pelleted, and resuspended in 4ºC freezing medium (50% FBS, 40% 
RPMI, 10% DMSO) at a density of 5 x 106 cells/ml [94].  The cells were placed in 
a Mr. Frosty, a storage device that uses isopropanol to slowly reduce the 
temperature of the freezing medium, and then stored overnight in a -80°C freezer 
before placing into a liquid nitrogen jacketed tank for long-term storage in the 
Biospecimen and Tissue Procurement Shared Research Facility (BSTP SRF).   
2.8 Thawing and stimulation of peripheral blood mononuclear cells 
 Samples of PBMCs were removed from liquid nitrogen storage and 
incubated at 37°C.  When the solution thawed, the cells were immediately 
transferred to tubes containing 37ºC thawing medium (50% FBS, 50% RPMI) at a 
ratio of 1 ml thawed cells to 10 ml of thawing medium.  An aliquot of cells was 
incubated with Trypan blue dye to evaluate cellular viability (which was greater 
than 90%). The remainder of the cells were then centrifuged (1200 RPM, 10 
minutes) to pellet the cells.  The supernatant was then removed and the cells 
were resuspended at a density of 1 million cells/ml of growth medium (20% FBS, 
80% RPMI, pen/strep and glutamine) containing the mitogen 
phytohaemagglutinin (PHA-P, from Sigma Aldrich) at a concentration of 10 µg/ml. 
PBMCs were then incubated at 37° C in 5% CO2 for 72 h and the repair assay 
was performed as described below. In the absence of PHA, which stimulates 
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cellular growth and division, we found that lymphocytes are not proficient in NER, 
similar to a previous observation that CPD repair was significantly impaired in 
unstimulated cells [95]. 
2.9 Measurement of NER – the immunoblot assay 
The removal of 6-4PPs and CPDs from total genomic DNA was measured 
using an immunoblot assay as previously described [96, 97] with some 
modifications. Cells were grown and treated with CSC or arsenic (when testing 
the impact of these agents on NER) as described above.  They were then 
washed twice with PBS and irradiated with UV-C light to introduce photolesions; 
20 J/m2 UV-C to measure the removal of 6-4 PPs and 2 J/m2 UV-C to measure 
the removal of CPDs. After irradiation, cells were either lysed immediately or 
after incubation for increasing periods of time to permit repair.  When testing the 
impact of CSC or arsenic on repair, the respective chemical was added back into 
the medium for the repair period after irradiation.  DNA was isolated using a 
Promega wizard genomic DNA isolation kit.  The concentration of the DNA 
samples from each time-point was measured using a fluorometer and Hoechst 
dye, which emits blue fluorescence when bound to dsDNA. The DNA was then 
denatured and equal amounts of DNA from each time-point were loaded onto a 
Hybond nitrocellulose membrane (Biorad) using a slot blot apparatus (100-200 
ng of DNA per slot for the detection of 6-4 PPs and 20 ng of DNA per slot for 
detection of CPDs). The membrane was baked in a vacuum oven at 80oC for 1 h, 
treated with 5 % nonfat dry milk (Blotto, Santa Cruz Biotechnology) in TBST (10 
mM Tris pH 8.0, 150 mM NaCl and 0.1% Tween-20) for 1 h, and incubated 
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overnight at 4o with mouse monoclonal antibodies (1:10,000 dilution) specific for 
either 6-4 PPs or CPDs (CAC-NM-DND-002, CAC-NM-DND-001, Cosmo Bio 
USA) in 1% dry milk and TBST.  The following day, the membrane was washed 
extensively with TBST and then incubated with goat anti-mouse horseradish 
peroxide-conjugated secondary antibodies (1:10,000 dilution, Thermo Scientific) 
in 1% dry milk and TBST for 2 h at room temperature. After washing, 
chemiluminescence (ECL – Plus, GE Healthcare Bio-Sciences Corp) and 
fluorimaging were used to detect the photolesions.  Image Quant computer 
software was employed to quantify the signal detected by the phosphorimager.  
The percent repair at each time point was calculated by dividing the signal 
strength of the slot-blot band obtained at each repair time point by the signal 
strength of the band obtained at the zero time point. For most membranes, a 
DNA ladder of irradiated DNA was used as an internal control for uniformity of 
slotting, antibody incubation and development with chemiluminescence.  
Unirradiated samples of DNA were also loaded to detect any nonspecific binding 
of the antibodies to DNA which in general was found to be insignificant.  
The immunoblot assay used to measure NER functions by inducing DNA 
damage and measuring clearance over time of the induced lesions.  The 
damaging agent used in the experiment was UV-C light, which introduces DNA 
photolesions.  Biologically, UV-C is absorbed by the ozone layer and as a result 
humans are almost never exposed to this wavelength of light.  Our rationale 
behind using this wavelength of light instead of UV-B/A was the quantity of 
photolesions introduced by UV-C from a given voltage is much higher than higher 
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wavelength UV bulbs.  This allows us to rapidly introduce DNA damage in a short 
period of time, minimizing the time cells are out of medium, and essentially 
eliminates the potential for repair to begin during the course of treating the cells 
with the damaging agents.  This is also why a chemical agent was not used to 
introduce DNA damage in the NER assay.  A variety of chemicals including BaP, 
acrolein, and AAF produce DNA damage that the NER complex would recognize 
and repair.  However, these chemicals require time to be absorbed into the cell, 
to reach the DNA, and to adduct to the DNA, and some even require cellular 
metabolism to become reactive to DNA, capable of binding and generating a 
DNA adduct.  Therefore, these chemicals require a significantly longer incubation 
time in the cellular medium than it takes to irradiate cells (30 seconds).  During a 
longer incubation period, the NER pathway is actively NER attempting to remove 
the DNA damage as it is being introduced.  A baseline damage point for all 
treatments is thus hard to achieve as any negative effect on repair would change 
the amount of DNA lesions present at “time zero” between treatments. 
2.9.1 Immunoblot assay for lymphocytes 
Lymphocytes stimulated with PHA were placed into 10 cm tissue culture 
plates at a density of 1 million cells per 1 ml stimulation medium (80% RPMI, 
20% FBS, 10 µg/mL PHA) and irradiated with 20 J/m2 UV-C to introduce 6-4 PP 
lesions. Cells were either lysed immediately after irradiation or after a period of 
time to permit repair of the damaged DNA.  At three points after irradiation (1, 2, 
4 hours) a portion of the irradiated cells were harvested and lysed.  The 
remainder of the repair assay was then carried out in the same fashion as 
described in section 2.9. 
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2.10 Western blot analysis  
The effect of CSC treatment on the abundance of XPC, XPA, and β-actin 
proteins in IMR-90 cells and BEAS-2B cells and the effect of arsenic treatment 
on the abundance of XPC, XPA, and β-actin proteins in IMR-90 cells and mouse 
keratinocyte cells were determined by Western blotting using mouse monoclonal 
antibodies (XPA for mouse cells: ab65963, Abcam;  XPA for human cells: sc-
56813; XPC: sc-74411, Santa Cruz Biotechnology; β-actin: A3854, Sigma). Cells 
were treated with different concentrations of CSC, sodium arsenite, or mock 
treated as described above for 24 h unless stated otherwise.  After treatment, 
cells were washed with PBS and trypsinized. Approximately five million cells 
were collected by centrifugation for each treatment, washed with PBS and stored 
at -20o or -80oC. Each sample of frozen cells was thawed on ice, resuspended in 
200 µl RIPA buffer (50 mM Tris (7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 
0.25% Na-Deoxycholate) containing 0.6 mM PMSF, 1% Protease Cocktail 
Inhibitor (Sigma) and 2 units of DNase 1 (New England BioLabs), lysed by 
sonication, centrifuged at 13,500 G to remove debris, and the amount of protein 
in each of the supernatants was quantified using the Bradford method.  
Alternatively, cells were counted, pelleted, directly lysed in loading dye and 
samples were loaded based on cell number.  Samples containing 100 µg of 
protein were mixed with loading dye, boiled at 100oC for 5 min, resolved in 8% 
(XPC/Actin) or 12% (XPA/Actin) SDS-PAGE gels and transferred to a PVDF 
membrane (Bio-Rad). The membranes were incubated for one h with 5% nonfat 
dry milk in TBST for blocking.  For XPC and ß Actin, the upper half of the 
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membrane was probed with a 1:1,000 dilution of XPC antibody and the lower half 
with 1:100,000 dilution of ß Actin antibody and incubated overnight at 4o C. The 
membrane was then washed extensively with TBST and incubated for 2 h with 
1:5,000 diluted HRP-conjugated goat anti-mouse antibodies (GE Healthcare Bio-
Sciences Corp) at room temperature. After extensive washing with TBST, the 
binding of antibodies was detected using enhanced chemiluminescence (ECL – 
Plus, GE Healthcare Bio-Sciences Corp) and fluorimaging. For XPA and ß Actin, 
the full membrane was probed with 1:1,000 dilution of XPA antibody overnight at 
4o C. Washing and development for XPA was performed in the same manner as 
XPC. The membrane was then stripped using a stripping buffer (Pierce) at 37o C 
for 15 min, washed with TBST, blocked and probed with ß Actin antibody. The 
amount of XPC or XPA in each lane was normalized to the amount of ß Actin in 
the same lane. 
2.11 Real-time PCR 
The effect of CSC or arsenite on the expression of XPC, XPA DDB2 
(arsenite only), and GAPDH RNA in IMR-90 cells was measured using Real-
Time PCR. Confluent cells were treated as described with CSC, arsenite, or their 
respective controls for 24 hours, washed with PBS, trypsinized, centrifuged, 
washed with PBS and pelleted. Total RNA was isolated from one million cells for 
each treatment using a GenElute mammalian total RNA Miniprep kit (Sigma). 
The RNA 6000 Nano Chip kit from Agilent was used to determine the quality and 
concentration of RNA isolated from the cells. For each treatment, 1.5 µg of RNA 
was reverse transcribed to cDNA using random primers and a high capacity 
38 
 
cDNA RT kit (Applied Biosystems). Primer sets specific to each gene were 
identified using the Universal Probe Library (Roche), and synthesized by 
Integrated DNA Technologies. Reactions were carried out on a Roche 
LightCycler 480 system using a 96-well plate format. Each reaction contained 1X 
Master Mix, 100 nM fluorescent reporter probe, 200 nM of each forward and 
reverse primer and 5 µl of cDNA (diluted 1:10). Samples were first incubated for 
10 min at 95oC followed by 40 cycles of amplification (95o C for 15 s denaturation 
and 60o C for 1 min annealing).  An equal volume of 1:10 diluted cDNA from 
each experimental treatment was mixed together to create the DNA that was 
used as a standard. Serial dilutions of mixed cDNA (1:1, 1:10, 1:100, 1:1,000, 
and 1:10,000) were used to create a standard curve. The expression levels of 
RNA in the treated cells were determined by comparing the crossing point (CP) 
values of the treated cells with the CP values of a standard curves for the 
corresponding gene or RNA. The crossing point is cycle of amplification during 
which the fluorescence of a sample achieves a threshold fluorescence above 
background. The amounts of XPC, XPA, or DDB2 RNA were normalized to the 
amounts of GAPDH RNA for each treatment. 
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Chapter 3 
 
Exposure of Human Lung Cells to Tobacco Smoke Condensate 
Inhibits the Nucleotide Excision Repair Pathway 
PLoS One. 2016 Jul 8;11(7):e0158858. doi: 10.1371/journal.pone.0158858. eCollection 2016 
 
3.1 Introduction 
Lung cancer is a deadly disease and a leading cause of cancer-related 
mortality in the US and in the world [98-100]. In 2012, the most recent year data 
is available, lung cancer accounted for 1.8 million cases of cancer and 1.6 million 
deaths worldwide [101, 102]. Exposure to tobacco smoke is the predominant risk 
factor for the development of lung cancer and it is estimated to account for 85-
90% of all lung cancer cases [103, 104]. It is also associated with the formation 
of tumors at additional sites in the body that are not directly exposed to smoke 
including the bladder, pancreas, liver, stomach and bone marrow [11, 105]. 
Tobacco use remains prevalent in certain regions of the world [106] and while its 
use has declined in the US, approximately 50% of newly diagnosed lung cancers 
occur in former smokers [103]. Hence, lung cancer and other forms of cancer 
associated with tobacco smoke exposure remain a tremendous health burden in 
the US and world-wide. Continued elucidation of the molecular mechanisms that 
lead to the formation of cancers associated with tobacco smoke is essential for 
prevention, treatment and identification of individuals who are at greatest risk for 
the development of cancer.  
Thousands of compounds have been identified in the vapor and 
particulate phases of cigarette smoke and they include carcinogens, co-
carcinogens, mutagens and tumor promoters. Approximately 70 of these 
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compounds have been classified as carcinogens [66, 104]. Different classes of 
chemical carcinogens are present in tobacco smoke including the polycyclic 
aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (B[a]P), 
dibenz[a,h]anthracene and dibenzo[a,l]pyrene. The DNA-reactive metabolites of 
PAHs are considered to be among the primary tobacco smoke carcinogens [67, 
104].  Metabolic activation of these and other chemical compounds found in 
tobacco smoke can generate intermediates that react with DNA bases and 
produce DNA adducts. Hence, DNA adducts are likely continually formed in the 
lung tissues of people who smoke, and if they are not removed by DNA repair 
processes, their persistence could lead to the formation of mutations. Many 
different types of genetic alterations are found in lung cancer and they include 
point mutations, genomic rearrangements, amplifications and large scale 
insertions and deletions. Mutations in KRAS and TP53 are frequently found in 
lung tumors and lung tissues of smokers [103, 107, 108], and the accumulation 
of mutations in these and other important oncogenes and tumor suppressor 
genes are driving forces in the development of lung cancer. 
PAH-induced DNA damage is removed by the nucleotide excision repair 
(NER) pathway [74, 75, 109-113] and hence, NER activity is likely critical to the 
prevention of carcinogen-induced mutations that contribute to neoplasia 
associated with smoke exposure. NER is a versatile pathway that removes a 
wide variety of structurally diverse DNA lesions including those generated by 
metabolites of chemical carcinogens as well as those generated by exposure to 
ultraviolet (UV) light. The cyclobutane pyrimidine dimer (CPD) and 6-4 
41 
 
photoproduct (6-4 PP), produced by UV light, are model substrates commonly 
studied when measuring NER activity as they are rapidly generated by a brief 
exposure to UV light [25]. In mammals, at least 20 different protein factors 
participate in NER, including the XPA-G factors that are singly defective in the 7 
corresponding complementation groups of the human disease, xeroderma 
pigmentosum (XP).  The tumor suppressor factor p53 also impacts NER 
efficiency probably by transcriptional regulation of the XPC and DDB2 gene 
products [20, 21, 114, 115]. The NER pathway is comprised of two sub-pathways 
that differ in their mechanism of damage recognition: global genomic NER (GG-
NER) which can remove damage from anywhere in the genome and 
transcription-coupled NER (TC-NER) which selectively removes damage from 
the transcribed strands of expressed genes.  In GG-NER, DNA damage 
recognition is accomplished by XPC, which is stabilized by its binding partners 
RAD23B, and CENTRIN2 [26].  In TC-NER, damage is recognized by the stalling 
of the RNA polymerase complex at the site of damage (reviewed in [24]).  After 
DNA damage recognition, many of the subsequent steps are the same for GG-
NER and TC-NER. The helicase activities of TFIIH produce additional unwinding 
of DNA where upon the endonuclease activities of the XPF/ERCC1 complex and 
XPG produce single-strand incisions flanking the damaged site.  The original 
integrity of the DNA is restored after an approximately 30 nucleotide region of 
DNA containing the lesion is removed, and the gap is filled by pol δ or pol ε, 
using the undamaged strand as a template (reviewed in [25]). 
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Several different types of animal models have been used to investigate 
the molecular mechanisms of lung cancer development caused by exposure to 
tobacco smoke. Unfortunately, many smoke inhalation studies have had limited 
success [116-118]. The A/J mouse model has been used extensively but it is 
confounded by the spontaneous lung tumors in control animals, need for long 
smoke exposure and recovery regimens, low tumor induction by smoke 
inhalation and responses that do not adequately mimic those found in humans 
exposed to tobacco smoke [116, 119]. Greater tumor incidence has been 
achieved by exposing female B6C3F1 mice to lifetime, whole-body mainstream 
tobacco smoke [118, 120].  The utilization of mice with targeted disruptions in 
tumor suppressor genes or oncogenes associated with lung cancer development 
in humans may yield improved animal models and additional mechanistic insights 
[121].  
As animal models for tobacco smoke exposure have had limited success, 
cigarette smoke condensate (CSC) has been used as a surrogate for cigarette 
smoke exposure to study its effects in model cell culture systems [105]. It is the 
particulate phase of cigarette smoke collected on Cambridge filters and 
resuspended in DMSO. It is mutagenic and genotoxic and produces several 
different types of mutations including point mutations, deletions, loss of 
heterozygosity (LOH),  microsatellite instability, sister chromatid exchanges and 
micronuclei [122-127]. It introduces DNA damage [127-130]. It also induces 
human and mammalian cell transformation [131-133] and tumor formation when 
applied to mouse skin [134-136]. While it is well established that cigarette smoke 
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introduces a variety of different types of DNA damage, it is less clear how smoke 
exposure influences DNA repair efficiency and DNA damage response pathways. 
Loss of DNA repair capability results in increased mutagenesis and 
carcinogenesis. In mouse models, deficiencies in NER have been associated 
with tumorigenesis at many organ sites including the lung [137]. Compared to 
normal mice, NER-deficient mice have a higher incidence of lung tumors when 
exposed to B[a]P [138, 139] and XPC-deficient mice have elevated levels of 
spontaneous lung tumors [140]. By extension, even a partial loss of NER 
efficiency in people is likely to increase mutagenesis and cancer incidence, 
particularly in cases of chronic DNA damage induction, as occurs in the lung 
tissue of smokers.  
We have studied the effects of CSC on the NER pathway using an 
immuno-slot blot assay to measure NER in two human lung cell lines; IMR-90 
and BEAS-2B.  We find a dose-dependent inhibition of the efficiency of NER 
when both cell lines are treated with increasing concentrations of CSC. 
Additionally, the impact of CSC on the abundance of various NER proteins and 
their respective RNAs was investigated.  We find that the abundance of XPC 
protein is significantly reduced when cells are treated with increasing 
concentrations of CSC, while the abundance of XPA protein is unaffected by 
treatment. Both XPC and XPA RNA levels are modestly affected by CSC 
treatment. Finally, a possible mechanism in which CSC inhibits XPC expression 
by altering protein turnover was investigated.  Our results provide evidence for 
the first time that CSC can directly interfere with the normal NER process, both in 
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terms of overall efficiency as well as at the protein and RNA level of NER factors, 
suggesting a possible new manner by which tobacco smoke may promote 
carcinogenesis.   
3.2 Statistical Considerations 
All statistical evaluations were done using Graph Pad Prism 6.  For the 
experiments comparing multiple treatments to a control, a 1-way ANOVA with a 
Holm-Sidak test for multiple-comparison was employed.  For the experiments 
comparing one treatment to a control, a Student’s T-test was employed. For all 
analyses, p<0.05 was used as the threshold for significance.  Statistical 
significance is described in the results section and not presented on the images 
as some graphs contained too many significant treatments to indicate on the 
graphs. 
3.3 Results 
3.3.1 CSC inhibits NER in IMR-90 cells 
We first investigated the effects of CSC on the NER pathway by studying 
a human lung fibroblast cell line, IMR-90.  The effect of CSC on cell viability was 
evaluated by treating cells with a range of different doses, 0 to 200 µg/ml, for 24 
h. No significant effect on viability was observed even after treatment of cells with 
200 µg/ml, the highest concentration of CSC used (Fig. 3.1A).  NER was studied 
using an immuno-slot blot assay that measures the removal of 6-4PPs or CPDs 
introduced by UV irradiation. These lesions are repaired exclusively by NER in 
human cells and 6-4PPs are model substrates to measure NER efficiency in total 
genomic DNA. In untreated cells, 6-4PPs are rapidly removed from DNA with the 
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majority of lesions removed within 3 h after UV irradiation. Treatment with CSC 
inhibits the removal of 6-4PP lesions in a dose-dependent fashion and the 
inhibition was statistically significant for all doses of CSC used (except 60 µg/ml) 
at one or more time points (Fig. 3.1B-C).  In general, NER in CSC treated 
samples was slowed but reached completion within 24 h after UV irradiation 
except when cells were treated with the highest dose of CSC, where both the 
kinetics and extent of repair were reduced. In contrast to the rapid removal of 6-
4PPs from genomic DNA found in untreated IMR-90 cells, the removal of CPDs 
in untreated cells was much slower. This observation of slow and inefficient 
removal of CPDs is similar to what other investigators have previously found in 
human cell lines using comparable doses of UV light [141, 142].  Treatment with 
CSC had only a minor inhibitory effect on the removal of CPDs (Fig. 3.1D-E), 
with a statistically significant difference only observed at the 48 h time point 
(p=.0435). The significance of this inhibition is difficult to evaluate since it was 
only seen at 48 h after UV irradiation. While the IMR-90 cells were studied in a 
confluent state, small differences in the amount of DNA replication at the 48 h 
time point could contribute to the differences in repair measured in the CSC-
untreated and treated samples.  
3.3.2 CSC reduces the abundance of XPC but not XPA protein in IMR-90 
cells 
The effect of CSC on the abundance of XPC and XPA protein was 
determined by western blotting using whole cell lysates of IMR-90 cells treated 
with 120, 160 and 200 µg/ml of CSC for 24 h. These are the same doses and 
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treatment time used to study the effects of CSC on NER. Whole cell lysates from 
mock treated cells (DMSO) were used as controls. The abundance of XPC 
protein was reduced in IMR-90 cells treated with increasing concentration of CSC 
for 24 h (Fig. 3.2A-B); XPC protein levels were reduced by 56% in cells treated 
with 200 µg/ml of CSC. The reduction in XPC protein compared to the mock 
treated cells was statistically significant in all treatments.  In contrast, there was 
not any statistically significant change in the abundance of XPA protein in cells 
treated with CSC (Fig. 3.2C-D).  The amounts of XPC and XPA proteins were 
normalized to the amounts of β actin present in each lane.  
3.3.3 A timecourse of CSC treatment shows a correlation between the 
reduction of XPC protein and the inhibition of NER 
Treatment of IMR-90 cells with CSC for 24 h inhibits NER and results in 
reduced expression of XPC protein. To measure the kinetics of these inhibitions, 
cells were treated with 200 µg/ml of CSC and the abundance of XPC protein was 
measured at 4 h intervals over a 24 h period and NER was measured after 
treatment with CSC for 8 h intervals over a 24 h period. A reduction in XPC 
protein compared to untreated cells was observed as early as 8 h and it was 
maximally inhibited by 16 h. The inhibition was statistically significant for all 
timepoints except 4 h (Fig. 3.3A-B).  Significant inhibition of NER was observed 
at all treatment times beginning with the 8 h treatment (Fig. 3.3C-D). NER was 
maximally inhibited with the longest length of treatment, 24 h, and a statistically 
significant difference from cells not treated with CSC was observed for all repair 
timepoints.  
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3.3.4 CSC modestly reduces XPC and XPA RNA levels in IMR-90 
The effect of CSC treatment on the abundance of XPC or XPA RNA in 
IMR-90 cells was measured using the same doses of CSC that were used to 
evaluate its effect on protein levels. No statistically significant changes in the 
abundance of XPC RNA were observed when cells were treated with 120 µg/ml 
or 160 µg/ml CSC, whereas a modest but statistically significant decrease was 
observed when cells were treated with 200 µg/ml of CSC (Fig. 3.4).  XPA showed 
modest, but significant, reduction in RNA expression across all CSC treatments.   
3.3.5 CSC inhibits NER and reduces the abundance of XPC protein in 
BEAS-2B cells 
We also investigated the impact of treatment with CSC on NER in a 
bronchial epithelial cell line, BEAS-2B.  We chose BEAS-2B cells due to the 
relevance of epithelial cells as sites of lung cancer formation, as they are the 
cells that line the respiratory tract and directly interact with inhaled carcinogens.  
The effect of CSC on cell viability was evaluated by treating cells with the same 
dose range chosen for IMR-90 viability (Fig. 3.5A).  Some toxicity was observed 
for BEAS-2B cells treated with CSC compared to little or no toxicity observed in 
IMR-90 cells (Fig. 1A). BEAS-2B were actively replicating at the time of 
treatment, and as a result they were likely more sensitive than IMR-90 cells to 
the toxicity of CSC. The effect of CSC on NER was then studied by measuring 
the removal of 6-4PPs after treatment with 175 µg/ml CSC for 16 h (Fig. 3.5B).  
In cells not treated with CSC, NER was rapid and efficient. Treatment with CSC 
resulted in significant inhibition of the removal of 6-4 PPs at all three time points 
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(Fig. 3.5C).  BEAS-2B cells were also treated with different doses of CSC for 16 
h and probed for XPC and XPA protein expression (Fig 3.5D).  A reduction in the 
abundance of XPC protein, but not XPA, was observed across the range of 
treatments of BEAS-2B cells with CSC (Fig 3.5E); similar to our findings in IMR-
90 cells.   
3.3.6 The reduction of XPC protein in IMR-90 cells by CSC treatment is 
mediated through the proteasome 
After observing that treatment of IMR-90 cells with CSC results in a 
significant reduction in the abundance of XPC protein, we investigated the 
potential influence of CSC treatment on ubiquitin mediated turnover of XPC.  UV 
irradiation induces ubiquitination of XPC protein [143] and XPC protein 
abundance has been previously linked to ubiquitin modification. After UV 
irradiation, XPC protein levels quickly drop in a proteasome dependent manner 
[144-146], although this appears to be both temporary and UV-dose dependent 
[143].  We also addressed this by treating IMR-90 cells with MG-132, which 
permits ubiquitin-linkages but prevents ubiquitin-mediated proteasomal 
degradation, and then exposing those cells to UV irradiation.  XPC levels were 
reduced after UV exposure, but in the presence of MG-132, this reduction was 
significantly diminished (Fig, 3.6A).  This confirms that UV-mediated XPC protein 
levels are altered in a proteasome-dependent manner.  We then asked whether 
the observed inhibition of XPC by CSC was also mediated by the proteasome.  
We treated IMR-90 cells with CSC in the presence of MG-132 for 16 h and 
observed that the reduction in XPC protein level produced by treatment with CSC 
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alone was almost completely abrogated by the addition of MG-132 (Fig. 3.6B).  
120 µg/ml CSC reduced XPC expression in the absence of MG-132, but in the 
presence of 1 and 5 µM MG-132, CSC did not inhibit XPC protein expression, 
suggesting that the inhibition of XPC protein expression by CSC requires 
functional proteasomal activity. 
3.4 Discussion 
In this study, we find that cigarette smoke condensate, a surrogate for 
tobacco smoke exposure, can inhibit NER function and reduce the expression of 
XPC, a key protein required for DNA damage recognition in the NER pathway. 
Consequently tobacco smoke exposure can affect the integrity of DNA in two 
fundamentally different ways. It is well established that it can introduce DNA 
damage, an important contributor to lung carcinogenesis. However, our findings 
indicate that, in addition, it can also inhibit the DNA repair pathway that is 
essential for the removal of some of the carcinogenic DNA damage introduced by 
smoke carcinogens. Hence, cells of the lung exposed to smoke would likely 
suffer an even greater DNA damage burden than previously held. Certain 
individual constituents of tobacco smoke have been implicated in inhibiting DNA 
repair.  Acrolein, a combustion product of cigarette smoke, has been shown to 
inhibit the nucleotide excision repair pathway and it inhibits XPC expression in a 
proteasome-dependent fashion [147-149].  In addition, arsenic, a metal 
constituent of tobacco smoke, has been found to reduce XPC expression [150]. 
Together, these studies suggest that components of tobacco smoke can impact 
lung carcinogenesis by inhibiting NER. CSC can also inhibit the base excision 
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repair (BER) pathway, which repairs oxidative DNA damage, another type of 
tobacco smoke damage [130, 131].  Hence, it will be important to investigate how 
tobacco smoke-induced alterations in different DNA repair pathways contribute to 
lung carcinogenesis.  
DNA damage recognition is an early, key step in NER and several studies 
suggest that DNA damage recognition by XPC is or can be the rate-limiting step 
in the pathway. Reduced expression of XPC has been associated with reduced 
repair of UV-induced photoproducts [151] and increased cancer incidence [47, 
152].   Biochemical and cellular studies indicate that the binding affinity of XPC 
for the DNA lesion or the time it takes XPC to find the DNA lesion may be the 
specific rate limiting step [28-30]. Conversely, complementation of an XPA 
deficient cell line with very low levels of XPA protein fully restores DNA repair 
activity [153] and XPA becomes rate limiting only when levels are reduced by 
over 90% [154, 155]; these studies suggest that the participation of XPA protein 
is usually not a rate limiting step in NER.  We find that treatment of cells with 
CSC inhibits NER and there is a concomitant reduction in XPC protein while XPA 
protein levels remain unchanged. If XPC protein is rate limiting in NER, then the 
inhibition of NER by CSC may be a direct consequence of the reduction in XPC 
protein. Additional genetic studies that manipulate the abundance of XPC during 
or after CSC treatment are needed to more directly establish the relationship 
between CSC induced alterations in XPC protein levels and its inhibition of NER. 
We find that treatment with CSC results in only a modest reduction in the levels 
of XPC RNA and it is only detected well after the amounts of XPC protein are 
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reduced. This suggests that most of the reduction in XPC protein produced by 
treatment with CSC is not caused by a reduction in XPC RNA. Lastly, an 
additional protein, UV DNA Damage Binding Protein 2 (UV-DDB2), is specifically 
required for the recognition and removal of CPDs in cells and functions in the 
turnover of XPC that can impact the removal of both CPDs and 6-4PPs. We 
attempted to examine the effect of CSC treatment on the abundance of DDB2 
but were unsuccessful in identifying an antibody that yielded results specific to 
the protein. 
Previous studies have demonstrated that XPC protein is polyubiquitinated 
after exposure to UV light and its polyubiquitination is mediated by the UV-DDB-
Ubiquitin ligase complex [143, 145, 156].  There are at least two distinct types of 
ubiquitin modifications to XPC following UV-induced DNA damage.  A lysine-48-
linked polyubiquitin linkage appears to promote degradation of XPC by the 
proteasome [157].  In contrast, a lysine-63-linked ubiquitination of XPC can be 
critical for the removal of XPC from the lesion site and allow downstream NER 
factors access to the DNA damage [158].  In addition, although the type of 
ubiquitin linkage was not determined, ubiquitin modification of XPC can actually 
increase its binding affinity for undamaged DNA [143]  XPC is also modified by 
sumoylation in response to UV damage [145] and inhibition of this modification 
reduces XPC stability after UV irradiation.  XPC SUMO modification has been 
implicated in promoting lysine-63 mediated XPC polyubiquitination [158, 159].  A 
recent report revealed seven unique UV-induced ubiquitination sites on XPC 
[160]. All of these studies demonstrate the complexity of the post-translational 
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modifications to XPC in response to DNA damage and they likely represent [81] 
the intricacies of regulating such an important and complex pathway.   
We observe that treatment with CSC results in a reduction in the 
abundance of XPC protein in the absence of UV damage, and that this reduction 
is reversed when cells are treated with MG-132.  This suggests that the reduction 
in the abundance of XPC protein produced by exposure to CSC is a 
consequence of enhanced proteasome-dependent turnover of the protein that is 
mediated by ubiquitination. XPC is intrinsically unstable as a monomer [161] and  
knocking down one of its binding partners, HR23B, promotes XPC degradation in 
a proteasome dependent manner [162].  Studies have also found that 
ubiquitination and proteasome-dependent turnover of XPC is important in 
maintaining steady-state levels of the protein in the absence of DNA damage 
[163]. In addition, the deubiquitinating enzyme USP-7 removes a UV-induced 
polyubiquitin chain from XPC that would otherwise target it for proteasome-
mediated degradation [146].  Hence, HR23B and USP-7 both function to stabilize 
XPC by inhibiting ubiquitin-mediated degradation. Since treatment with CSC can 
result in the introduction of different forms of DNA damage (discussed below), it 
is possible that the induced turnover of XPC by the proteasome is mediated 
through the introduction of certain types of DNA damage. Additional studies are 
needed to determine if CSC-mediated turnover of XPC functions by promoting 
ubiquitination or inhibiting deubiquitination and to characterize the sites of 
ubiquitination. CSC has been previously shown to enhance the proteasome-
mediated turnover of Akt, a protein kinase [164], which together with our studies 
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may indicate that smoke exposure can impact multiple pathways by targeting 
specific proteins to the proteasome for degradation.  
The assay used to measure NER in this study measures the introduction 
and removal of UV light-induced photoproducts. We chose to use this approach 
because it provides a method to rapidly introduce DNA damage and it precisely 
quantitates the kinetics of removal of a model substrate for the NER pathway. 
Moreover, the use of UV light as a DNA damaging agent is not confounded by 
variations in cellular uptake or metabolic activation as can be the case when 
using chemical agents to introduce DNA damage. It is likely that CSC would 
inhibit the removal of other substrates for NER but additional studies are required 
to investigate its effect on the removal of chemical modifications to DNA 
introduced by tobacco smoke.  Tobacco smoke contains a number of compounds 
capable of producing DNA lesions, several of which are repaired by the NER 
pathway, including BPDE.  The BPDE lesion can be particularly important in the 
etiology of smoking-related lung cancer, as the G-T transversion signature 
mutation of BPDE [70, 76, 81, 105, 165] is found more frequently in at CpG 
mutational hotspots in the P53 gene of lung tumors from smokers compared with 
lung tumors from non-smokers [78, 166, 167].  Mice exposed topically to B[a]P 
develop skin tumors with the same signature mutations in p53 [168].  Hence, 
measuring the effect of CSC on the removal of BPDE adducts is important to 
directly demonstrate that tobacco smoke exposure inhibits the repair of DNA 
damage introduced by the tobacco smoke itself. In our study, it is likely that any 
adducted base damage directly introduced by the CSC treatment was very small 
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compared to the levels of photoproducts introduced by UV irradiation. Thus, it is 
unlikely that the inhibition of NER by CSC treatment was due to a competition 
between different types of DNA damage introduced during the experiments or 
titration of the NER pathway by damage directly introduced by CSC.  
3.5 Conclusions 
Cigarette smoking remains the highest risk factor for lung cancer 
development in the United States and the world.  However, not all smokers 
develop lung cancer.  Our results suggest that CSC, a commonly accepted 
surrogate for tobacco smoke exposure, inhibits the NER pathway, increasing the 
persistence of lesions in DNA.  In addition, CSC reduces the abundance of XPC 
protein, a key protein required for DNA damage recognition in NER, and this 
reduction is likely produced by targeting XPC to the proteasome for degradation. 
It is well established that variations in DNA repair capacity contribute to cancer 
risk, and our findings indicate that inhibition of NER is another mechanism by 
which smoking may contribute to development of lung cancer. Therefore, it may 
be prudent to consider measuring individual DNA repair capacity as a means of 
evaluating lung cancer risk, particularly among people who have other risk 
factors. 
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Figure 3.1. CSC inhibits NER in IMR-90 human lung fibroblasts. 
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Figure 3.1. CSC inhibits NER in IMR-90 human lung fibroblasts. (A) Cell 
viability after CSC treatment. Confluent IMR-90 cells were treated with CSC (or 
mock treated with DMSO) with the concentrations shown for 24 h and the 
percentage of viable cells was measured using Trypan blue dye exclusion. The 
data represent the mean ± SE (Standard Error) from four independent 
experiments (except for 60 µg/ml CSC which included two independent 
experiments). (B) Removal of 6-4 PPs. Cells were treated with the concentrations 
of CSC shown or with DMSO for 24 h and irradiated with 20 J/m2 UVC to 
introduce photolesions. After irradiation, cells were either lysed immediately or 
after incubation in medium containing CSC or DMSO for the times (h) shown to 
permit repair.  The immunoblot assay to detect 6-4 PPs was performed and 
samples were loaded in duplicate for each repair time point. (C) Removal of 6-4 
PPs. A graphical representation of results obtained from multiple immunoblots 
measuring the removal of 6-4 PPs is shown. Each data point represents the 
mean ± SE of three repeats from two independent experiments.  (D)  Removal of 
CPDs. IMR-90 cells were treated with 200 µg/mL CSC or with DMSO for 24 h 
and irradiated with 2 J/m2 UVC to introduce photolesions.  After irradiation, cells 
were either lysed immediately or after incubation in medium containing CSC or 
DMSO for the times shown to permit repair.  An immunoblot assay to detect CPD 
lesions was performed and samples were loaded in triplicate for each time point.  
(E) Removal of CPDs. A graphical representation of results obtained from 
multiple immunoblots measuring the removal of CPDs is shown.  Each data point 
represents the mean ± SE of three repeats from two independent experiments. 
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Figure 3.2. CSC reduces the abundance of XPC, but not XPA, protein in 
IMR-90 cells. 
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Figure 3.2. CSC reduces the abundance of XPC, but not XPA, protein in IMR-
90 cells. (A) Cells were treated with different concentrations of CSC as shown for 
24 h, and the abundance of XPC was examined by western blot analysis.  (B) A 
graphical representation of multiple western blots for XPC expression is shown.  
The data presented are the mean ± SE from two repeats each of three independent 
experiments, and XPC expression was normalized to β-actin. (C) Cells were 
treated as shown for 24 h, and the abundance of XPA was measured by western 
blot analysis.  (D) A graphical representation of multiple western blots for XPA 
expression is shown. The data presented are the mean ± SE of three repeats from 
three independent experiments, and XPA expression was normalized to β-actin.   
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Figure 3.3. The impact of CSC on XPC protein and NER efficiency depends 
on treatment duration.  
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Figure 3.3. The impact of CSC on XPC protein and NER efficiency depends 
on treatment duration. (A) IMR-90 Cells were treated with 200 µg/ml of CSC for 
the times indicated and XPC expression was examined by western blot analysis.  
(B) A graphical representation of multiple western blots examining the time course 
of inhibition for XPC expression after CSC treatment is shown. The data presented 
are the mean ± SE of three repeats from one experiment, and XPC expression 
was normalized to β-actin.  (C) Results of an immunoblot showing the time course 
of the effect of CSC on repair of 6-4 PPs in IMR-90 cells.  Cells were treated with 
200 µg/mL CSC for 8, 16, or 24 h (or DMSO for 24 h) and irradiated with 20 J/m2 
UVC to introduce photolesions.  After irradiation, cells were either lysed 
immediately or after incubation in medium containing CSC or DMSO for the times 
shown (3, 6 and 8 h) to permit repair.  An immunoblot assay was performed and 
samples were loaded in duplicate to measure the removal of 6-4 PPs.  (D) A 
graphical representation of multiple immunoblots for 6-4 repair is shown.  Each 
data point represents the mean ± SE of three repeats from one experiment.  
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Figure 3.4. The effect of CSC on the abundance of XPC and XPA RNA in IMR-
90 cells.  
 
 
Figure 3.4. The effect of CSC on the abundance of XPC and XPA RNA in IMR-
90 cells. Cells were treated with the indicated concentrations of CSC (or DMSO) 
for 24 hours. RNA was isolated and Real Time PCR was performed as described 
in the methods section. The expression of XPC or XPA RNA was normalized to 
GAPDH RNA for each treatment. The data presented are the mean ± SE of one 
analysis from three independent experiments. 
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Figure 3.5. CSC inhibits NER and the abundance of XPC protein in BEAS-2B 
cells. 
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Figure 3.5. CSC inhibits NER and the abundance of XPC protein in BEAS-2B 
cells. (A) Cells were treated with the concentrations of CSC shown for 16 h and 
the percentage of viable cells was measured using Trypan blue dye exclusion. The 
data presented are the mean ± SE of four biological experiments.  (B) Cells were 
treated with 175 µg/mL CSC (or DMSO) for 16 h, and irradiated with 20 J/m2 UVC 
to introduce photolesions.  After irradiation, cells were either lysed immediately or 
after incubation in medium containing CSC or DMSO for increasing periods of time 
to permit repair.  An immunoblot assay was performed and samples were loaded 
in duplicate to measure the removal of 6-4 PPs. (C) A graphical representation of 
multiple immunoblots for 6-4 repair is shown.  Each data point represents the mean 
± SE of four repeats from one experiment.  (D) Cells were treated with the different 
concentrations of CSC shown for 24 h, lysed, and the abundance of XPC and XPA 
were examined by western analysis. (E) A graphical representation of multiple 
western blots for XPC and XPA protein is shown.  The data presented are the mean 
± SE of two repeats from two independent experiments for XPC and three repeats 
of one experiment for XPA.  XPC and XPA values were normalized to β-actin. 
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Figure 3.6. Involvement of the proteasome in the reduced expression of XPC 
protein in IMR-90 cells after treatment with UV or CSC. 
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Figure 3.6. Involvement of the proteasome in the reduced expression of 
XPC protein in IMR-90 cells after treatment with UV or CSC. (A) Cells were 
treated with 10 µM MG-132 or untreated for 4 hours, and then irradiated with 20 
J/m2 UV-C.  After irradiation, cells were either lysed immediately or after 
incubation for increasing periods of time in the same type of medium as was 
used for the pretreatment; medium containing MG-132 or not containing MG-132. 
XPC expression was measured using Western blot analysis.  (B) A graphical 
representation of the experiments from (A) is shown.  XPC expression was 
normalized to β-actin.  The data presented are the mean of two repeats from one 
experiment.  The percent XPC protein was calculated by comparing post-UV time 
points to the appropriate 0 h (MG-treated or not MG-treated) time point.  
Treatment with MG-132 for 4 h had a negligible impact on XPC expression 
before irradiation, so both 0 h values were set to 100%. (C) Cells were treated 
with a combination of CSC and/or MG-132 at the indicated concentrations for 16 
h.  XPC levels were measured by Western blot analysis and normalized to Actin. 
(D) A graphical representation of the average obtained from two different blots for 
the experiments in (C) is shown; treatment with 3 µM MG-132 was not included.  
XPC expression was normalized to β-actin. 
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Chapter 4 
Inorganic arsenic inhibits the nucleotide excision repair pathway 
and reduces the expression of XPC protein 
http://dx.doi.org/10.1016/j.dnarep.2017.02.009 
4.1 Introduction 
 Inorganic arsenic is a metalloid found in moderate levels in the Earth’s 
crust. It is one of the world’s oldest known carcinogens [169] and it is classified 
as a class I carcinogen [170]. Humans can be exposed to arsenic by drinking 
contaminated water [171], inhaling certain substances in occupational settings 
[170], ingesting contaminated food (summarized in [172]) and using tobacco 
products [173]. It is estimated that approximately 200 million people in the world 
are exposed to drinking water contaminated with potentially harmful levels of 
arsenic [174]. In the US, exposure to contaminated drinking water occurs in 
many regions throughout the country [175]. According to the Agency for Toxic 
Substances and Disease Registry (ATSDR), arsenic ranks number one on the 
priority list of hazardous substances found at National Priority List sites 
(http://www.atsdr.cdc.gov/SPL/index.html). 
Exposure to arsenic increases the risk for cancer development at multiple 
organ sites including the skin [176-178], lung [179, 180], liver (summarized in 
[181]), and bladder [182].  Arsenic has been used for centuries for a range of 
medicinal purposes, and topical treatment with an arsenic compound called 
Fowler’s solution (discovered in 1786) was used to treat a host of diseases 
including malaria, syphilis, asthma, chorea, eczema, and psoriasis [183]. It was 
over one hundred years later that Hutchison proposed that Fowler’s solution was 
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a human skin carcinogen [184].  Correlations between arsenic exposure and 
internal cancer development were first observed in regions of the world where 
populations were exposed to levels of arsenic between 10-100 fold greater than 
the 2002 EPA standard and current World Health Organization Guideline level of 
10 µg/L in drinking water [185].  In these regions of the world, such as parts of 
Bangladesh, India, China, Argentina, Chile, and other countries (Reviewed in 
[175]), high arsenic contamination in the water is a consequence of local 
geographical deposits of the metal and poor procedures for decontaminating 
water.  In the US, exposure to arsenic is generally more moderate. However, it 
has been estimated that arsenic concentrations exceed 20 µg/L in 5% of 
regulated water systems [175] and arsenic exposure in the US has been 
tentatively linked to skin [186], bladder [187] and lung cancers [83].  Interestingly, 
arsenic has also been adopted as a chemotherapeutic agent, with arsenic 
trioxide (ATO) used with success to treat acute promyelocytic leukemia [188-
190].  
Arsenic exposure likely contributes to cancer development by multiple 
mechanisms. Evidence indicates that arsenic impacts genotoxicity, although it 
does not directly interact with DNA to produce DNA damage (reviewed in [84]). 
Rather than directly producing DNA damage, arsenic is often considered a co-
carcinogen that influences the mutagenicity and carcinogenicity of other agents.  
Co-treatment of cells with arsenic and UV light results in a reduction in the 
removal of photoproducts produced by UV light [191-193] and an increase in 
mutation rates produced by UV light [193-196].  Co-treatment of cells with 
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arsenic increases the levels of DNA adducts produced by benzo[a]pyrene diol-
epoxide (BPDE) which is a metabolite of benzo[a]pyrene (B[a]P), a compound 
present in tobacco smoke [197, 198]. Consistent with this observation, arsenic 
reduces the removal of BPDE adducts [199, 200] and increases the frequency of 
mutations formed by BPDE [201]. These observations are directly relevant to the 
types of cancer associated with exposure to arsenic; specifically, arsenic 
increases non-melanoma skin cancer and lung cancer incidences in humans for 
which UV light and tobacco smoke exposure, respectively, are risk factors [177, 
202]. 
Several studies have investigated how arsenic may act as a co-
carcinogen using mouse models.  When added to drinking water, arsenic 
enhances the production of DNA damage and the mutagenicity of topically 
applied B[a]P, but it does not produce mutations or DNA damage in the absence 
of B[a]P [203, 204].  Arsenic increases the multiplicity and size of skin tumors 
produced by dimethylbenz[a]anthracene (DMBA), a polycyclic aromatic 
hydrocarbon (PAH), but it does not alter skin carcinogenesis in the absence of 
DMBA [205, 206].  It also greatly increases the formation of UV-induced skin 
tumors in hairless mice [207], but it does not induce tumor formation in the 
absence of UV damage [208]. 
Many of the agents that arsenic interacts with as a co-mutagen or co-
carcinogen, including UV light and tobacco smoke, produce DNA lesions that are 
removed by the nucleotide excision repair (NER) pathway. UV light produces 
cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4 PPs), both 
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substrates for NER [209].  Tobacco smoke contains several classes of chemicals 
which can react with DNA, forming adducts that are removed by NER. Multiple 
polycyclic aromatic hydrocarbons (PAHs) from combustion of tobacco (as well as 
fossil fuels and other organic matter) produce bulky, DNA distorting adducts that 
are generally repaired by NER. PAH-induced adducts include (+)-trans-BPDE-
N2-dG, the primary stereoisomeric adduct formed by B[a]P, which is clearly 
removed by NER (reviewed in [75]).  Tobacco smoke also contains a class of 
aromatic amines called 4-aminobiphenyls (4-ABP) which can produce DNA 
adducts recognized by NER, including N-(deoxyguanosin-8-yl)-4-aminobiphenyl 
(dG-C8-ABP) [210]. 
The NER pathway removes helix-distorting DNA lesions which can cause 
mutations and drive carcinogenesis.  This is clearly illustrated by decades of 
investigation of the disease Xeroderma Pigmentosum (XP). Patients with XP are 
deficient in NER and have greatly elevated levels of skin cancer and other forms 
of cancer [40, 42, 211].  In mammals, at least 20 different proteins participate in 
NER, including the XPA-G factors that are singly defective in the 7 corresponding 
complementation groups of XP [25, 212, 213].  The tumor suppressor factor p53 
also impacts NER efficiency probably by transcriptional regulation of the XPC 
and DDB2 genes [20, 21, 114, 115].   NER, sometimes referred to as global 
genomic NER (GG-NER), can remove damage from anywhere in the genome.  A 
subpathway of NER called transcription-coupled NER (TC-NER) selectively 
removes damage from the transcribed strands of expressed genes.  These two 
pathways differ in their mechanism of DNA damage recognition.  In NER, DNA 
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damage recognition is accomplished by XPC, which is stabilized by its binding 
partners RAD23B and CENTRIN2 [26] and is assisted by the UV-damaged DNA 
binding protein DDB2 (the product of the XPE gene).  In TC-NER, damage is 
recognized by the stalling of the RNA polymerase complex at the site of damage 
(reviewed in [24]).  After DNA damage recognition, the subsequent steps are the 
same for NER and TC-NER. The multi-subunit complex TFIIH contains helicase 
activities that produce additional unwinding of DNA, which produces double-
strand/single-strand DNA junctions.  After DNA unwinding several NER 
components are recruited to the site of the lesion, including XPA, which is likely 
used to verify the presence of the DNA lesion and that the required NER factors 
are present for the subsequent steps of the pathway.  Next, the endonuclease 
activities of the XPF/ERCC1 complex and XPG produce single-strand incisions 
flanking the damaged site.  The original integrity of the DNA is restored after an 
approximately 30 nucleotide region of DNA containing the lesion is excised, and 
the gap is filled by pol δ or pol ε, using the undamaged strand as a template, with 
DNA ligase IIIα or DNA ligase I filling in the final nick in the DNA (reviewed in 
[25]). 
The molecular mechanisms by which arsenic may act as a co-carcinogen 
are under debate.  One possibility is that arsenic inhibits the removal of DNA 
damage produced by carcinogens such as UV light and certain compounds 
present in tobacco smoke, thus exacerbating their mutagenic effects. NER has 
been suggested as a candidate pathway since it removes the DNA damage 
introduced by these agents [150, 200, 214-217].  In the present study, we have 
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examined the impact of arsenic (as the trivalent ion arsenite) on NER using an 
immuno-blot assay to directly measure DNA lesions specifically removed by 
NER.  NER function was inhibited with increasing concentrations of arsenite in 
both human fibroblasts and mouse keratinocytes.  Additionally, NER protein and 
RNA levels were measured in both cell types in response to arsenite treatment, 
and a concentration-dependent decrease in XPC protein and XPC, XPA, and 
DDB2 RNA levels was observed.  Finally, a possible mechanism in which 
arsenite inhibits XPC protein expression by altering protein turnover was 
investigated.  Our findings support the hypothesis that arsenic can promote 
carcinogenesis by interfering with the NER-specific repair of DNA damage 
introduced by other carcinogens, and provides insights into how arsenic may 
additionally function as an anti-cancer drug, especially in tandem with DNA 
damage-inducing chemotherapeutics. 
4.2 Results 
4.2.1 Statistical considerations 
All statistical evaluations were done using Graph Pad Prism 6.  All 
experiments involved comparing multiple treatments to a control, and therefore a 
1-way ANOVA with a Holm-Sidak test for multiple-comparison was employed.  For 
all analyses, p<0.05 was used as the threshold for significance.   
4.2.2 Arsenite inhibits NER in primary mouse keratinocyte cells 
 We investigated the impact of treatment with arsenite on NER in primary 
mouse keratinocytes.  Arsenic can be a co-carcinogen in skin cancer 
development and squamous cell and basal cell carcinoma originate from 
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keratinocytes located in the skin.  First, the effect of arsenite on mouse 
keratinocyte cell viability was evaluated across a range of arsenite exposures 
(Fig. 1A).  Toxicity was moderate across the treatment range, with the highest 
exposure producing ~50% toxicity.  After examining the effects of arsenite on cell 
viability, the effect of arsenite on NER was studied using an immuno-slot blot 
assay that uses lesion-specific antibodies to measure the removal of 6-4 PPs or 
CPDs introduced by UV irradiation.  These lesions are removed exclusively by 
NER in rodent and human cells, although CPDs are a poorer substrate for NER 
and require a longer period of time to be removed from DNA [218, 219].  In cells 
exposed to arsenic, they were pretreated with arsenic for 24 h, irradiated with UV 
and arsenic was added to the medium for the duration of the repair interval. In 
keratinocytes not treated with arsenite, 6-4 PPs were rapidly removed from DNA, 
with the majority of lesions removed within 4 h after UV irradiation. In contrast, 
treatment with arsenite resulted in a concentration-dependent inhibition of the 
removal of 6-4 PPs compared to untreated cells (Fig. 1B).  20 µM arsenite 
significantly inhibited 6-4 PP removal at the 8 and 24 h timepoints, while 40 µM 
arsenite significantly inhibited 6-4 PP removal at the 4, 8, and 24 h timepoints.  
Arsenite treatment also inhibited the removal of CPDs in mouse keratinocytes 
(Fig. 1C).  The UV-C dose used to measure the removal of CPDs was 
considerably lower than that used to measure removal of 6-4 PPs (2 J/m2 
compared to 20 J/m2) since CPDs are introduced at a much higher frequency 
than 6-4 PPs. 20 µM arsenite significantly inhibited the removal of CPDs at the 
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48 h timepoint, and the 40 µM treatment significantly inhibited the removal of 
CPDS across all of the timepoints measured. 
4.2.3 Arsenite reduces the abundance of XPC, but not XPA, protein in 
primary mouse keratinocyte cells 
The effect of arsenite on the abundance of XPC and XPA was determined 
by western blotting using whole cell lysates isolated from mouse keratinocytes 
treated for 24 h with the indicated concentrations of arsenite (Fig 2A). The 
amounts of XPC and XPA at each concentration are presented in reference to 
their amounts in untreated cells, with normalization for the amount of β-actin 
present in the same lane (Fig. 2B-C). The abundance of XPC was reduced in 
cells treated with increasing concentration of arsenite (Fig. 2B); XPC levels were 
reduced by 40% in cells treated with 10 µM arsenite, the lowest concentration 
tested.  The reduction increased to 59% and 81% for the 20 and 40 µM arsenite 
treatments.  The amount of reduction compared to untreated cells was 
statistically significant for each concentration of arsenite administered. In 
contrast, the abundance of XPA was not significantly affected by arsenite 
treatment, except at the highest exposure (Fig. 2C).   
4.2.4 Arsenite inhibits NER in IMR-90 cells 
 We also investigated the effects of arsenite on the NER pathway by 
studying the human lung fibroblast cell line, IMR-90.  First, the effect of arsenite 
on cell viability was evaluated by treating cells with the indicated concentrations 
for 24 h (Fig. 3A). Treatment with arsenite produced some moderate toxicity at 
exposures ≥15 µM, with 40 µM producing an approximate 50% reduction in 
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viability.   NER was studied as described.  Treatment with ≥20 µM arsenite 
resulted in a concentration-dependent inhibition of the removal of 6-4 PPs 
compared to untreated cells.  The removal of 6-4 PP lesions was significantly 
slowed in all the arsenite treatments, across all timepoints measured (except As-
20 at 2, 4 and 6 h) (Fig. 3B). No significant effect on the removal of 6-4 PPs was 
observed when cells were treated with 10 µM arsenite for 24 h (data not shown).   
Second, IMR-90 cells were treated for a longer period of time, 48 h,  with a 
reduced range of arsenic concentrations (0-15 µM arsenite) and cell viability and 
the removal of 6-4 PPs was measured (Supplemental Fig. 1). When cells were 
treated with arsenic for 48h, the medium was removed after 24 h of treatment 
and replaced with fresh medium containing the same concentration of arsenic. 
Treatment of cells with 10 or 15 µM arsenite for 48 h produced little toxicity 
(Supplemental Fig. 1A) but resulted in a significant inhibition of the removal of 6-
4 PPs compared to untreated cells at all timepoints except the 3 h timepoint of 
the 10 µM arsenite treatment (Supplemental Fig 1B).  At these lower doses, the 
amount of inhibition observed was similar, likely due to technical limitations of the 
assay to differentiate small differences in NER efficiency. Thus, we observe that 
arsenic inhibits the removal of 6-4 PPs after treatment with higher concentrations 
for 24 h and after treatment with lower concentrations for 48 h.  The impact of 
arsenite on the removal of CPDs was also investigated.  When cells were treated 
with 20 or 40 µM arsenite for 24 h and irradiated with 2 J/m2 UV light, the 
removal of CPDs was inhibited in a statistically significant fashion at multiple 
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timepoints (12 and 48 h timepoints for 20 µM arsenite, all timepoints for 40 µM 
arsenite) (Fig. 3C). 
4.2.5 Arsenite reduces the abundance of XPC, but not XPA, protein in IMR-
90 cells 
The effect of arsenite on the abundance of XPC and XPA was determined 
by western blotting using whole cell lysates isolated from IMR-90 cells that were 
treated for 24 h with different concentrations of arsenite.  Whole cell lysates 
isolated from untreated cells were used as controls. The amounts of XPC and 
XPA were normalized to the amount of β-actin in the same lane. The abundance 
of XPC was reduced in IMR-90 cells treated with increasing concentrations of 
arsenite (Fig. 4A); XPC levels were reduced by 40% in cells treated with 10 µM 
arsenite, the lowest exposure tested.  Inhibition increased to 70 and 85% for the 
20 and 40 µM arsenite treatments.  The reduction in the abundance of XPC in all 
three treatments compared to untreated cells was statistically significant (Fig 4B).  
XPA levels were also examined after arsenite treatment (Fig 4C).  In contrast to 
XPC, only the highest concentration of arsenite produced a modest but 
significant 25% reduction in the abundance of XPA (Fig 4D).  
4.2.6 Arsenite reduces XPC, XPA, and DDB2 RNA levels in IMR-90 cells 
The effect of arsenite treatment on the abundance of XPC, XPA, and 
DDB2 RNA in IMR-90 cells was measured by real-time PCR, using the same 
treatment conditions used to evaluate its effect on protein levels.  Arsenite 
significantly reduced RNA expression of all three genes in a concentration-
dependent fashion (Fig. 5).  Changes in the abundance of XPC and XPA RNA 
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were observed at 20 and 40 µM arsenite, whereas DDB2 expression was 
severely reduced even at the lowest exposure, 10 µM arsenite. 
4.2.7 The reduction of XPC protein in IMR-90 cells by arsenite treatment is 
mediated through the proteasome 
 After observing that treatment of IMR-90 cells with arsenite results in a 
significant reduction in the abundance of XPC protein, we investigated the 
potential influence of arsenite treatment on ubiquitin-mediated degradation of 
XPC.  As XPC is modified by ubiquitin [143, 145, 156], we hypothesized that 
arsenite may inhibit XPC abundance in a manner that is regulated by the 
proteasome.  To test this hypothesis, we treated IMR-90 cells with arsenite in the 
presence or absence of the proteasomal inhibitor MG-132 for 16 h and measured 
XPC by Western blotting (Fig. 6A).  In cells treated with arsenic alone, we 
observed a reduction in XPC expression similar to the levels seen in Fig. 4A. 
When cells were co-exposed to arsenic and MG-132, the reduction in XPC 
expression was eliminated, and expression levels were maintained at a level 
similar to untreated cells (Fig. 6B).  These findings suggest that proteasomal 
degradation of XPC is at least partially responsible for the observed reduction in 
XPC protein levels upon treatment with arsenite.   
4.3 Discussion 
In this study, we use an immuno slot-blot method to directly measure the 
removal of UV photoproducts and we find that arsenic, in the trivalent form of 
sodium arsenite, inhibits the efficiency of NER.  Treatment with arsenite 
significantly inhibits the removal of 6-4 PPs and CPDs in two different cell types; 
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human IMR-90 lung fibroblasts and primary mouse keratinocytes.  In addition, we 
find that treatment with arsenite reduces the abundance of XPC protein and 
XPC, XPA and DDB2 RNA. Others have investigated the effects of arsenic on 
the efficiency of NER using a variety of different assays. Arsenite has been found 
to interfere with the production of repair-related DNA strand breaks in general 
and alters DNA incision and ligation frequencies in human fibroblasts exposed to 
UV light, more indirect measurements of NER [214-217]. An early observation of 
an inhibitory effect of arsenite on the efficiency of NER was made studying the 
removal of thymine dimers using chromatography in a Chinese hamster ovary 
(CHO) cell line measured 24 h after UV irradiation [192].  More recently, arsenite 
treatment of human lymphoblastoid TK6 cells was found to slow the removal of 
UV-induced DNA damage as measured by the Comet assay 2 h after UV 
irradiation [193] and arsenite treatment of a mouse keratinocyte cell line was 
found to delay the removal of 6-4 PPs introduced by solar simulated UV radiation 
[191]. Therefore, our findings extend and add to the understanding of how 
arsenic alters NER and possibly contributes to arsenic-mediated carcinogenesis. 
We observed some increase in cellular toxicity when cells were treated 
with different concentrations of arsenic.  While the inhibition of NER can sensitize 
cells to cell death and apoptosis [220-222], it is unclear how apoptosis or cell 
death may impact the efficiency of NER.  There was a 10 fold difference in the 
doses of UV light used in our experiments to measure the removal of 6-4 PP and 
CPD lesions (20 J/m2 for 6-4 PPs and 2 J/m2 for CPDs).  However, we found that 
the inhibition of NER found after treatment with arsenic was significant regardless 
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of whether the cells were treated with a lower or higher dose of UV light; this 
suggests that the inhibition of NER in response to treatment with arsenic was not 
solely brought about changes in toxicity. In addition, when we treated cells with 
lower concentrations of arsenic for a longer period of time, 48 h instead of 24 h, 
toxicity was markedly reduced, but we still observed a significant inhibition in 
removal of 6-4 PPs.  
Our observations of the impact of arsenic on cellular expression of NER 
proteins and RNA levels also extend previous studies. Treatment of human skin 
fibroblasts with arsenic reduced the expression of XPC and DDB2 at both the 
protein and RNA levels, but the efficiency of NER was not measured [150].  We 
observe that treatment with arsenic significantly reduces XPC protein in human 
IMR-90 lung fibroblasts and primary mouse keratinocytes but we were unable to 
measure DDB2 protein since we were unsuccessful in identifying an antibody 
that yielded results specific to the protein. We also observe a reduction in XPC, 
XPA, and DDB2 RNA levels in IMR-90 cells treated with arsenic. Our observation 
of a reduction in XPA RNA but not XPA protein after treatment with some 
concentrations of arsenic might be due to a relatively high abundance of XPA 
protein or low turnover of the protein. Interestingly, arsenic exposure has also 
been linked to a reduction in RNA levels of several NER genes in a human 
population, including ERCC1, XPF, and XPB, but not XPA (XPC and DDB2 RNA 
levels were not measured) [223].   
Several studies have proposed mechanisms by which arsenic can inhibit 
NER function.  One study observed that arsenic reduces the expression of XPC 
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(and DDB2) protein and RNA in human skin fibroblasts, and these reductions 
also correlated with a reduction in the recruitment of XPC to sites of DNA 
damage [150].   The mechanism by which arsenic reduced XPC expression or 
whether treatment with arsenic impacted the efficiency of the removal of DNA 
damage was not explored, in contrast to our study. Additionally, arsenic inhibits 
the removal of BPDE adducts in A549 human lung cells and it can displace zinc 
from a peptide representing the zinc finger domain of XPA at high exposures (as 
judged by 19% zinc release when the peptide was treated with 100 µM arsenite) 
[199].  Since the zinc finger domain has been shown to be important for the 
function of XPA in NER [224], arsenic may disrupt NER by altering the structure 
of XPA, but additional studies are needed to explore these findings. In addition, 
methylated metabolites of arsenite were found to be considerably more efficient 
than the parental arsenical in displacing zinc from XPA, and inhibited the removal 
of BPDE lesions at lower concentrations [199].  
We observe that treatment with arsenic inhibits NER function and reduces 
XPC expression.  XPC is ubiquitylated in response to UV-induced DNA damage 
[143, 145, 156].  There are multiple ubiquitin modifications to XPC following the 
introduction of UV-induced DNA damage. These include a lysine-48-linked 
polyubiquitin linkage that appears to promote degradation or recycling of XPC 
[157] and a lysine-63-linked ubiquitination of XPC that can be critical for the 
removal of XPC from the damaged site to allow downstream NER factors access 
to the DNA damage [158].  The deubiquitinating enzyme USP-7 is responsible for 
removing a UV-dependent ubiquitin linkage to XPC, and this promotes XPC 
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stability [146].  We tested whether the reduction of XPC protein expression that 
we observe after treatment of IMR-90 cells with arsenic is related to proteasomal 
turnover of XPC.  We observe that the proteasomal inhibitor MG-132 abrogated 
the effects of arsenite in reducing XPC protein levels. This indicates that the 
reduction in the abundance of XPC produced by exposure to arsenic is, at least 
in part, a consequence of enhanced proteasome-dependent turnover of the 
protein that is mediated by ubiquitination.  Additional studies are needed to 
determine if arsenic-mediated turnover of XPC functions by promoting 
ubiquitination or inhibiting deubiquitination and to characterize the sites of 
ubiquitination. Furthermore, arsenic’s effects on the proteasome may not be 
limited to altering the expression of XPC and may have an influence on the 
stability of other proteins and pathways.   
Given our observation that XPC RNA is also reduced by arsenite 
treatment, arsenic-mediated reduction in XPC expression may not be solely a 
result of increased proteasomal turnover of XPC.  However, inhibiting 
proteasomal activity with MG-132 fully restored XPC expression in the presence 
of arsenic, indicating that proteasomal turnover of XPC is responsible for the 
majority of the observed reduction of XPC protein abundance.  Had the reduction 
in XPC levels by arsenic treatment been primarily a consequence of reduced 
transcript levels, MG-132 would not have been able to restore XPC expression to 
levels seen in untreated cells.  Additionally, treatment with MG-132 alone did not 
result in an increase in XPC abundance. This suggests that the steady state 
turnover of XPC is fairly low in undamaged cells, and this observation is 
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consistent with results of a previous study where XPC levels were unchanged for 
up to nine hours when XPC turnover was inhibited [225].  Consequently, the 
increase in XPC protein in cells treated with MG-132 and arsenic relative to cells 
treated with arsenic alone is not a result of MG-132 increasing XPC above basal 
levels, but rather a function of inhibiting the turnover of XPC mediated by arsenic.  
Nevertheless, the relative contributions of the reduction in XPC RNA and the 
increase in XPC turnover to the overall arsenite-dependent reduction in XPC 
needs further study.   
We studied the effects of arsenic on the NER pathway in light of previous 
associations made between exposure to arsenic and elevated frequencies of 
lung and skin cancer in humans [176, 179] and elevated frequencies of skin 
cancer in UV-exposed mice [207, 208]. The primary risk factor for lung cancer is 
exposure to tobacco smoke and the primary risk factor for skin cancer is 
exposure to solar UV irradiation. Tobacco smoke introduces many types of DNA 
damage, including the highly studied PAHs such as B[a]P.  BPDE, the ultimate 
metabolite of B[a]P, produces large bulky adducts that are recognized and 
removed by the NER pathway [75, 109, 111].  BPDE adducts produce a 
characteristic mutational signature, and this signature is found more frequently in 
lung cancers of smokers than non-smokers [78, 166, 167].  Sun exposure 
introduces DNA lesions which are also recognized by NER [25, 209].  In non-
melanoma skin cancer, mutational signatures characteristic of exposure to UV 
light are observed in the p53 gene and are present at mutational hotspots [226], 
indicating that these NER substrates can be causative in the production of non-
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melanoma skin cancer.  Melanocytes are more resistant to UV induced 
cytotoxicity than are keratinocytes, the epidermal skin cells responsible for most 
non-melanoma skin cancers.  This difference may explain the observation that 
arsenic increases the cancer incidence of non-melanoma skin cancers [227] 
while the relationship between arsenic and melanoma development is less 
clearly established [228, 229].  Since deficiencies in the removal of BPDE 
adducts or UV-induced photolesions by NER result in increased mutation levels, 
the inhibition of NER by arsenite could explain how arsenic can act as a co-
carcinogen in smoking-related lung and UV-related skin cancers.  
In general, humans are exposed to arsenic for a substantial period of time, 
such as when they are exposed to contaminated drinking water (which can occur 
for years), or when they are treated with arsenic-based chemotherapies (which 
can occur for several weeks [188]). In contrast, treatment of cells in culture 
usually involves a single, much shorter exposure to arsenic which often 
necessitates the use of higher than physiological concentrations to observe 
measurable effects. Chronic treatment of cells with low concentrations of arsenite 
can induce cellular transformation [230-233], global DNA hypomethylation [231-
234], local DNA hypermethylation [234, 235], alterations in chromatin structure 
and splicing patterns [230], and increases in oncogenic gene expression [232, 
236].  Recent research has indicated that chronic arsenic exposure alters 
methylation patterns of DNA repair factors involved in NER, leading to reduced 
RNA expression of ERCC1 and ERCC2 [237].  These epigenetic changes likely 
contribute to arsenic-mediated carcinogenesis, but chronic treatment of cells in 
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culture with lower, physiological concentrations would likely complicate 
investigations and interpretations of direct effects on DNA repair.  Additional 
studies in human populations are important to determine if chronic exposure to 
lower concentrations of arsenic through contaminated drinking water or arsenic-
based chemotherapy inhibits the efficiency of NER in a human populations.  
Several previous studies, some described above, and our study have 
investigated the effects of arsenic on NER using single treatments of at least 10 
µM arsenic [150, 192, 199, 200]. These concentrations are higher than what 
humans would usually encounter during long term chronic exposure to 
contaminated drinking water. However, they are within the range of 
concentrations used to sensitize chemo-resistant cells to killing by 
chemotherapeutic agents such as doxorubicin [238], paclitaxel [239], erlotinib 
[240], and cisplatin [241].  Of particular interest is the finding that arsenic 
treatment sensitizes chemo-resistant cancer cells to killing by cisplatin. Cisplatin 
generates DNA adducts that are substrates for NER. Hence, co-treatment with 
arsenic may sensitize cells to cisplatin by inhibiting the NER pathway [241]. The 
same study also found that treatment with arsenic reduced expression of XPC, 
and that disruption of the XPC gene in the absence of arsenic treatment 
sensitized the chemo-resistant cancer cells to killing by cisplatin.   These studies 
and our study suggest that disruption of the NER pathway by treatment with 
arsenic should be explored to enhance the efficacy of chemotherapeutic agents 
used to treat cancer.   
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While several studies have indicated that arsenic increases the mutation 
frequency of other carcinogens such as UV-light [193-196] and components of 
tobacco smoke [201, 203], relatively few studies have investigated the impact 
arsenic plays on the types of mutations found in co-exposed systems.  While not 
a measurement of mutagenesis, co-exposure of arsenic and benzo[a]pyrene 
increased the frequency of adducts produced by benzo[a]pyrene in mice [204].  
In cultured CHO cells, co-treatment with arsenic and UV-light increases mutation 
frequency by a factor of two relative to cells exposed to UV-light alone, and the 
mutational spectrum in the co-treated cells retained a UV-signature [242]. Very 
few studies have examined the spectra of mutations produced in human skin 
cancers related to human exposure to arsenic.  In one single study of an arsenic-
exposed population of skin cancer patients, the mutations found in p53 were at 
different codons than the normal hotspots seen in the p53 gene of UV-induced 
skin cancers [243]. However, all the tumor samples in this single study were 
obtained from areas of the body not generally exposed to sunlight, and hence it 
is unlikely that UV light played any major role in the etiology of these tumors.  
Consequently, it is clear that additional studies are important to investigate the 
mutational spectra found in skin tumors derived from sun exposed areas of the 
body in individuals exposed to arsenic. These studies should aid in 
understanding whether the alterations to the efficiency of NER that we have 
observed in our study also occur in humans exposed to arsenic, and if so, 
whether they play a role in increasing mutational burden and the risk of 
developing cancer.   
85 
 
Fig 4.1. Arsenic inhibits the removal of 6-4 PPs and CPDs in primary mouse 
keratinocytes. 
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Figure 4.1.  (A) Primary mouse keratinocytes were treated with the indicated 
concentrations of arsenite for 24 h and the percentage of viable cells was 
measured using Trypan blue dye exclusion. The data represent the mean ± SE 
(Standard Error) from two independent experiments.  (B) Primary mouse 
keratinocytes were treated with the indicated concentrations of arsenite for 24 h, 
irradiated with 20 J/m2 UV-C, and incubated in the same concentration of As-
containing medium for the times shown. An immuno slot-blot assay was 
performed and removal of the 6-4 PP lesion was measured.  A graphical 
representation of the results obtained from multiple immunoblots measuring the 
removal of 6-4 PPs is also shown. Each data point represents the mean ± SE of 
4-5 repeats of one biological experiment (5 repeats of 0 and 10 doses, 4 repeats 
for 20 and 40 doses).  (C) Primary mouse keratinocytes were treated with the 
indicated concentrations of arsenite for 24 h, irradiated with 2 J/m2 UV-C, and 
incubated in the same concentration of As-containing medium for the times 
shown. An immuno slot-blot assay was performed and the removal of CPDs was 
measured.  A graphical representation of the results obtained from multiple 
immunoblots measuring the removal of CPDs is also shown. Each data point in 
the graph represents the mean +/- SE of three repeats from one independent 
experiment.  Treatments with arsenic that produced a significant difference (P 
<0.05) compared to the control treatment are designated with an asterisk.  For 
the repair assay, each treatment was compared to the untreated cells at the 
same timepoint after irradiation. 
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Figure 4.2. Arsenic reduces XPC, but not XPA, protein in primary mouse 
keratinocytes. 
 
Figure 4.2. (A) Primary mouse keratinocytes were treated with the indicated 
concentrations of arsenite for 24 h, and the abundance of XPC and XPA protein 
was examined by western blot analysis.  Graphical representations of multiple 
western blots for XPC (B) and XPA (C) protein are shown. The data presented 
are the mean ± SE from two repeats each of one independent experiment, and 
the amount of XPC or XPA protein were normalized to β-actin.  Treatments with 
arsenic that produced a significant difference (P <0.05) compared to the control 
treatment are designated with an asterisk. 
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Figure 4.3. Arsenic inhibits the removal of 6-4 PPs and CPDs in IMR-90 
human lung fibroblasts 
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Figure 4.3. (A) IMR-90 cells were treated with the indicated concentrations of 
arsenite for 24 h and the percentage of viable cells was measured using Trypan 
blue dye exclusion. The data represent the mean ± SE from seven independent 
experiments. (B) IMR-90 cells were treated with the indicated concentrations of 
arsenite for 24 h, irradiated with 20 J/m2 UV-C, and incubated in the same 
concentration of As-containing medium for the times shown.  An immuno slot-blot 
assay was performed and removal of the 6-4 PP lesion was measured.  A 
graphical representation of the results obtained from multiple immunoblots 
measuring the removal of 6-4 PPs is also shown.  Each data point in the graph 
represents the mean +/- SE of four repeats from one experiment. (C) IMR-90 
cells were treated with the indicated concentrations of arsenite for 24 h, irradiated 
with 2 J/m2 UV-C, and incubated in the same concentration of As-containing 
medium for the times shown. An immuno slot-blot assay was performed and the 
removal of CPDs was measured.  A graphical representation of the results 
obtained from multiple immunoblots measuring the removal of CPDs is also 
shown. Each data point in the graph represents the mean +/- SE of at least three 
repeats from one experiment (two repeats of one experiment for the 40 µM 
dose).  Treatments with arsenic that produced a significant difference (P <0.05) 
compared to the control treatment are designated with an asterisk. For the repair 
assay, each treatment was compared to the untreated cells at the same 
timepoint after irradiation.    
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Figure 4.4. Arsenic reduces the abundance of XPC, but not XPA, protein in 
IMR-90 cells.  
 
Figure 4.4. (A) IMR-90 cells were treated were treated with the indicated 
concentrations of arsenite for 24 h, and the abundance of XPC was examined by 
western blot analysis.  (B) A graphical representation of multiple western blots for 
XPC expression is shown.  The data presented are the mean ± SE from two 
repeats each of three independent experiments, and XPC expression was 
normalized to β-actin. (C) IMR-90 cells were treated with the indicated 
concentrations of arsenite for 24 h, and the abundance of XPA was measured by 
western blot analysis.  (D) A graphical representation of multiple western blots for 
XPA expression is shown. The data presented are the mean ± SE of three 
repeats from three independent experiments, and XPA expression was 
normalized to β-actin.  Treatments with arsenic that produced a significant 
difference (P <0.05) compared to the untreated cells are designated with an 
asterisk. 
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Figure 4.5. The effect of sodium arsenite on the abundance of XPC and XPA 
RNA in IMR-90 cells. 
 
Figure 4.5. IMR-90 cells were treated with the indicated concentrations of 
arsenite for 24 h. RNA was isolated and Real Time PCR was performed as 
described in the methods section. The expressions of XPC, XPA, and DDB2 
RNA were normalized to GAPDH RNA for each treatment. The data presented 
are the mean ± SE of two repeats of three independent experiments for XPC, 
and XPA, and one repeat of three independent experiments for DDB2.  
Treatments with arsenic that produced a significant difference (P <0.05) 
compared to the untreated cells are designated with an asterisk. 
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Figure 4.6. Involvement of the proteasome in As-mediated XPC inhibition
 
Figure. 4.6. (A) IMR-90 cells were treated with a combination of arsenite and/or 
the proteasome inhibitor MG-132 at the indicated concentrations for 16 h.  XPC 
levels were measured by Western blot analysis and normalized to Actin. (B) A 
graphical representation of multiple Western blots for XPC is shown.  The data 
presented are the mean of two repeats from two experiments (except MG-only 
treatments, which are the mean of two treatments of one experiment), and XPC 
expression was normalized to β-actin.   
93 
 
Supplemental Table 4.1. Primers used in quantitative real-time PCR 
analysis  
 
S. Table 4.1. Multiple primer pairs were used to measure XPC and XPA RNA 
expression, and the resulting analysis did not produce any measurable difference 
between primer pairs within a single gene, so both primer pairs were included in 
the analysis of these genes.  
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Supplemental Figure 4.1. Extending arsenite treatment time enhanced 
arsenite impairment of 6-4 PP removal 
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S. Figure 4.1 A) IMR-90 cells were treated with the indicated concentrations of 
arsenite for 48 hours with the medium changed every 24 hours and the 
percentage of viable cells was measured using Trypan blue dye exclusion. The 
data represent the mean ± SE (Standard Error) from three measurements of one 
independent experiment.  (B) IMR-90 cells were treated with the indicated 
concentrations of arsenite for 48 hours, irradiated with 20 J/m2 UV-C, and 
incubated in the same concentration of As-containing medium for the times 
shown. A representative slot blot and a graph of multiple immunoblots measuring 
removal of 6-4 PP are shown.  Each data point in the graph represents the mean 
+/- SE of three repeats from one independent experiment. Asterisks denote a 
significant difference between the treated sample and the control at a given 
timepoint, as measured by a 1-way ANOVA with a multiple comparison 
correction. 
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Chapter 5 
Establishment of a reproducible measure of individual NER 
efficiency in peripheral blood mononuclear cells  
5.1 Introduction 
Nucleotide Excision Repair (NER) is a multi-protein complex designed to 
repair a variety of exogenous and endogenous DNA lesions and prevent 
mutation formation [244].  The NER pathway is divided into two sub-pathways 
that recognize different components of the genome.  Global genomic NER (GG-
NER) utilizes the XPC protein in complex with HR23B and Centrin-2 to recognize 
a remarkable array of DNA damage found on non-transcribed DNA, which is the 
majority of DNA [26].  Damage present on the transcribed strand of DNA is 
recognized by an RNA polymerase stalling at a transcription blocking lesion, 
leading to recruitment of downstream factors in the transcription-coupled NER 
(TC-NER) sub-pathway (reviewed in [24]).  After DNA damage recognition, both 
pathways use common factors for the remaining steps.  The TFIIH transcriptional 
complex is recruited to the site of damage to unwind the DNA around the lesion, 
with two helicases creating further opening the DNA, which permits subsequent 
NER factors to assemble at the site of the lesion.  Two endonucleases, 
XPF/ERCC1 and XPG, then nick the damaged strand on the 5’ and 3’ sides of 
the lesion, respectively.  The oligonucleotide containing the DNA adduct is 
removed and a DNA polymerase resynthesizes the gap using the undamaged 
strand as a template [25]. The NER pathway is described in more detail in 
chapter 1. 
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Individuals suffering from xeroderma pigmentosum (XP), one of three rare 
genetic disorders associated with deficiencies in NER, exhibit a pronounced 
increase in cancer incidence, both external and internal [25], with certain types of 
skin cancer showing incidence rates over a thousand fold greater than the 
general population [245].  XP is a hereditary autosomal recessive disorder, with 
XP A-G subtypes corresponding to the XPA-XPG proteins involved in NER [246].  
The frequency of XP varies greatly between geographical regions, with a 
frequency of approximately 1 in 1,000,000 in Western Europe and the United 
States [247] but 1 in 22,000 in Japan [43].  Carriers of XP have been studied to 
determine the health consequences of this heterozygosity.  XP-A heterozygotes 
have proficient DNA repair faculties [44], while XP-C heterozygotes have an 
intermediate phenotype regarding XPC mRNA and protein expression [46].  This 
may explain why low levels of XPA can correct the UV sensitivity of XP-A 
deficient cell lines [153] while reduced XPC expression correlates with reductions 
in repair of UV-induced photo-damage [248] and increased cancer risk for certain 
head and neck cancers [47] .  Another study of the impact of NER gene 
expression levels on head and neck cancer risk indicated that XPC expression 
did not correlate to increased cancer risk, while ERCC1, XPB, XPG, and CS-B 
levels did [249], indicating that expression levels of individual NER factors may 
not be the most appropriate marker for cancer risk. 
In addition to expression levels of NER factors, polymorphisms in genes 
involved in NER have also been examined for their potential to contribute to 
cancer susceptibility.  The polymorphism frequency of XP genes varies 
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considerably (reviewed in [250]), so it is hard to give a single estimate of XP 
polymorphism frequency.  Despite that, XP polymorphism frequency is 
sufficiently large to contribute to the population variation in DNA repair capacity 
[251, 252]. Recent meta-analyses have reached different conclusions regarding 
XP gene polymorphisms and cancer risks, with some showing certain XP 
polymorphisms contribute to carcinogenesis [253-255], while others show no 
relationship [256] or conflicting results from the same polymorphism between 
studies [250, 257].  While certainly not conclusive, these results suggest that 
certain XP gene polymorphisms may contribute to increased cancer incidence.  
These studies also indicate there is a potential for many different genetic 
polymorphisms to contribute to cancer risk. Given this, polymorphisms in one or 
even a handful of genes may not fully reveal and individual’s cancer 
susceptibility.  Instead, measuring DNA repair is an aggregate measure of 
steady-state NER function and as a single value can be used as indicator of 
individual cancer risk. 
Previous studies have investigated DNA repair capacity (DRC) in isolated 
lymphocytes using methods including the host-cell reactivation assay [246, 258-
260] and the comet assay [94, 261-263].  Several studies have used the 
measurement of DRC in circulating lymphocytes as an indicator of individual 
cancer risk [259, 264-266].  These lymphocytes are used as surrogate cells when 
investigating DRC in a target tissue because of the non-invasive manner by 
which they can be obtained and because target tissue may have undergone 
exposure-mediated somatic changes [19].  Additionally, a positive correlation 
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between DRC in lymphocytes and target tissues in XP patients has been 
observed [267], reinforcing the utility of lymphocytes as an appropriate measure 
of patient DRC.   
Current research on DNA repair of isolated human lymphocytes often 
employs the host cell reactivation (HCR) assay, which functions by measuring 
repair of a damaged plasmids transfected in to the cell.  The HCR assay also 
requires transcription of the reactivated gene on the plasmid that is being 
measured as an indicator of effective repair, involving other pathways beyond 
DNA repair in order to measure repair.  The immuno-blot assay we have adapted 
to work with isolated lymphocytes accurately and reproducibly measures NER 
efficiency directly, and the lesions introduced are done so in a stochastic manner 
that does not involve cellular uptake or metabolism.  Also, the output value from 
a host-cell reactivation assay is a percentage of activity of the reporter gene. It 
does not provide any information about NER kinetics  
An additional method for measuring DNA repair in isolated lymphocytes, 
the Comet assay, can be adapted to specifically measure repair of UV-induced 
photolesions.  The comet assay uses an electronic charge to separate double-
stranded DNA from single-stranded DNA.  Greater quantities of DNA damage 
produce larger amounts of single-stranded DNA.  In order to make the assay 
specific to one type of DNA damage, like UV-induced photolesions, damage-
specific endonucleases can be added.  T4 endonuclease V cuts at sites of UV-
induced CPDs, and as such provides a manner with which one can adapt the 
Comet assay to specifically measure the amount of CPDs present in a cell.  
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However, the 6-4 PP lesion is repaired much more proficiently than the CPD 
lesion in human cells, and as such greater variations in removal of the 6-4 PP 
lesion can be seen in a shorter period of time than compared to removal of the 
CPD lesion. 
Recent work in our lab has provided insights into how the NER pathway 
can be modified by exposure of cells in culture to certain carcinogens such as 
tobacco smoke [268] and arsenic (Chapter 4).  These studies suggest that 
human exposure to these agents may contribute to changes in NER efficiency, 
but a human study has not been performed using the same repair assay, and it is 
unknown what other factors may affect NER efficiency in a human population.  
Herein we report our findings pertaining to the establishment a novel method for 
measuring DRC in isolated lymphocytes using an assay to measure NER 
efficiency, specifically the sub-pathway known as global genomic NER, using a 
modified immuno-slot blot repair assay.  We found reproducible measurements 
of NER efficiency across multiple repeated measures from the same sample, as 
well as between experiments performed on multiple batches of lymphocytes 
isolated from the same individual and even between different blood draws from 
the same individual.  Additionally, we observed a distribution of repair values in 
our study population that was similar to DRC distributions found using the HCR 
assay. Our findings suggest this method is a reliable measurement of individual 
DNA repair capacity and that it is capable of capturing population variation in 
DNA repair, which indicate that the measurement of NER efficiency may be a 
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suitable biomarker of cancer risk and may be used to study the effect of 
environmental exposures on NER efficiency. 
5.2 Results 
5.2.1 Statistical analysis 
The immunoblot repair assay provided a repair curve that showed the 
percentage of 6-4 PPs removed at different timepoints after irradiation.  We 
determined that the most effective way to present this data was to create a single 
value that could explain the repair efficiency of each individual.  We chose to 
calculate a half-life statistic, a value that represented the time, in hours, that was 
required by each individual to remove 50% of the introduced photolesions.  
Briefly, an immunoblot (Fig. 5.1A) is used to calculate the percentage of 
photolesions that have been removed at each timepoint, and these values are 
plotted on a linear axis (Fig. 5.1B).  This is then converted from percentage 
lesions removed to percentage lesions remaining, and those values are plotted 
on a log-scale y-axis (Fig. 5.1C).  When a log-scale axis plot such as this 
produces a linear graph, the data is best fit to an exponential decay curve.  So, 
an exponential decay regression analysis was performed and used to calculate 
“half-life.” The process of calculating this value from the regression analysis is 
explained in detail in chapter 6. 
Normality tests for population distribution of half-life were performed using 
SAS 9.3 software, and comparisons of half-lives between populations were done 
using Graph Pad Prism 6, using a 2-sided Student’s T-test with a threshold of 
significance of P < 0.05. 
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5.2.2 Study population 
 The subjects for this study were part of a case-control study examining 
lung cancer rates in Appalachian Kentucky.  Lung cancer patients of the case-
control study were identified through the Kentucky Cancer Registry, and healthy 
control subjects were identified from the Kentucky voter registration records.  
Control subjects were age and gender matched to the lung cancer cases using a 
frequency matching method.  All participants were required to be over 17, and 
had to have no prior history of cancer diagnosis, excepting stage I or II non-
melanoma skin cancers.  They were required to have a working phone, to be 
willing to consent to an in-person interview, and to be able to speak English 
without the use of an interpreter.  The individuals whose lymphocytes were 
analyzed for repair represent a random sampling of the subjects in the case-
control study at a 1:3 ratio of lung cancer cases to control subjects.  In all, 42 
cancer patients and 156 control subjects were analyzed for DRC.  A greater 
number of subjects provided blood samples, but low lymphocyte yields from the 
blood or high non-lymphocyte contamination of the buffy coat prevented us from 
performing the repair analysis on those samples.  Initially, additional 6 lung 
cancer subjects were part of the study population, but they received radiation 
therapy.  After it was determined that those who received radiation therapy had a 
significantly different (higher) average half-life than those who did not, they were 
removed from the study population.  In fact, only 25% of samples from individuals 
who received radiation therapy were stimulated and provided a measurable 
repair value – the remainder had insufficient lymphocyte yields to perform the 
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stimulation or did not respond properly to the stimulation process.  We also 
evaluated half-life values from individuals who received chemotherapy and those 
who had undergone surgery related to their lung cancer, and neither of those 
populations had a different half-life than the remainder of the cancer subjects, so 
they remained in the study (Supplemental Figure 5.1).  Additionally, a smaller 
second study of 33 lung cancer patients from Kentucky was analyzed using the 
same repair assay, and the data from that assay was used to confirm the levels 
of experimental variation in individual DRC measurements.  The repair assay 
was performed blindly to reduce any potential biases in conducting the repair 
experiments. A statistician with information about the demographics of the study 
participants provided us with a list of samples to stimulate that was age and 
gender matched between cases and controls (although some exclusions after the 
analysis shifted the gender distribution slightly). The identification of the subjects 
as lung cancer cases or controls was withheld until the analysis was completed, 
and were revealed after completion of the repair analysis in order to perform 
comparisons between cases and controls, which will be discussed in Chapter 7. 
5.2.3 Experimental variation of repair capacity 
 Of the 198 samples analyzed, the average coefficient of variation (CV, 
standard deviation/average) of the half-life was 11%, slightly higher than a 
reported CV using HCR as a measure of repair in isolated lymphocytes [258], but 
considerably lower than more recent reporting of  23% [266] and 26.2% [269].  
The population showed a wide range of NER efficiency, with half-lives ranging 
from 1.5 to10.7 hours.  The average and standard deviation are 4.17 and 1.77 
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hours respectively.  A distribution of the data indicates that the data seems fairly 
normally distributed with a slight right tail (Fig. 5.2A).  However, a Kolmogorov-
Smirnov (K-S) statistical test for normality indicates that it is not normally 
distributed (p < 0.01).  Certain statistical analyses such as ANOVA assume a 
normal distribution (although they can tolerate minor deviations from normality) 
and therefore skewed data are often transformed with a mathematical operation 
(such as a natural-log transformation) to normalize the data set.  The distribution 
of the natural-log transformed half-life values (Fig. 5.2B) is normally distributed 
using the same K-S test for normality (p > 0.150).  Thus, when needed, a normal 
data set can be generated from the half-life values produced by the repair assay, 
strengthening value of the repair assay as it relates to the types of analyses that 
can be performed on the half-life values generated. 
5.2.4 Replication of the repair assay 
 Experimental reproducibility is critical.  We performed two independent 
stimulations of lymphocytes isolated from twelve study participants (7 from the 
larger study and 5 from a smaller, second study).  These stimulations were 
tested independently for their half-life, and Table 5.1 shows the half-life and 
standard error of these repeat stimulations, along with a p-value from a Student’s 
T-test comparing the two half-life values.  The first and second stimulations of 
these lymphocytes produced half-life values that were not statistically different.  
Of particular interest, one study participant (individual 12 in Table 1) had blood 
drawn on two separate occasions, and the repeat stimulations came from these 
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separate blood draws, suggesting the half-life value from the repair assay is 
reproducible across different blood draws of the same individual. 
5.2.5 Impact of different experimental parameters on NER efficiency 
 We examined the effect of three recovery parameters - blood volume, 
lymphocyte yield, and DNA recovery – on the half-life value produced by the 
repair assay.  The lymphocyte yield is the number of cells in a milliliter of blood 
counted before the cells are frozen for storage, and the DNA recovery is the 
concentration of DNA recovered from the first timepoint in the repair assay 
divided by the number of cells stimulated for that timepoint.  These three factors 
had quite large ranges: the volume of blood collected for the study ranged from 
5.5 ml to 18.1 ml, the amount of lymphocytes recovered from this blood ranged 
from 0.76 to 5.84 million cells/ml blood, and the DNA recovery ranged from 0.41 
to 4.07 micrograms of DNA/million cells.   With these large ranges, particularly 
the lymphocyte and DNA recoveries, it was unknown what effect, if any, they 
might have on the reliability of the assay.  These recovery parameters were 
plotted against the half-life of each individual in the study.  A graph showing the 
relationship between blood volume and half-life (Fig. 5.3A) indicates there is no 
significant impact on half-life due to the blood volume. A linear regression 
analysis of the scatter plot provided an R2 value of 0.0148 (p = 0.09).  Likewise, a 
comparison of lymphocyte recovery to half-life (Fig. 5.3B) also indicates that cell 
recovery did not have a significant impact on half-life.  A linear regression 
analysis provided an R2 value of 0.018 (p = 0.06).  Interestingly, a plot of DNA 
recovery verses half-life showed a minor reduction in half-life (increase in repair) 
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with increasing DNA recovery (Fig. 5.3C).  While technically significant (p = 
0.037), the linear regression equation indicates that an increase in DNA recovery 
of 2 µg DNA per 1 million cells stimulated (over half of the entire range of DNA 
recoveries in the study) only produces a 1-hour increase in half-life, and it is 
unclear whether the DNA recovery was a cause or a result of changes in NER 
efficiency. 
5.2.6 Impact of the time delay between blood draw and lymphocyte 
isolation on NER efficiency 
Previous reports have suggested that there is an optimal maximum time 
delay between blood draw and lymphocyte isolation, in order to maximize post-
thaw cell viability and response to mitogen stimulation.  This delay is the most 
important factor affecting cellular recovery and viability [270], with lymphocyte 
recovery dropping substantially when samples sit for 24 hours rather than 8 
hours before isolation.  It was unknown, however, how this delay would affect 
cellular DNA repair using our repair assay, so we compared the time delay 
between blood draw and lymphocyte isolation to several experimental 
parameters.  Increasing the time delay increased the number of cells recovered 
per milliliter of blood provided (Fig. 5.4A).  This may be misleading, however, as 
non-monocyte contamination may have increased in the buffy coats of samples 
that were delayed in their shipment [271].  Prolonged storage of blood alters 
granulocyte buoyancy and impairs proper separation from mononuclear cells by 
use of a density gradient, increasing granulocyte contamination in the monocyte 
buffy coat layer [272].  Increasing processing time also reduced DNA recovery at 
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the first timepoint in the repair assay, perhaps a consequence of a reduced 
response to mitogen stimulation in samples with longer processing time (Fig. 
5.4B).  Despite the change in cell count at isolation and DNA recovery during the 
repair assay, there was no change in NER efficiency based on processing time 
(Fig. 5.4C).  
The majority of samples (n = 179) had time delays that clustered around 
24 hours. A small number of samples (n = 19) had time delays that clustered 
around 48 hours, a result of a shipping issue that was corrected after the sample 
collections were underway.  As most studies do not exceed a 24 hours 
processing delay, this provided a unique opportunity to observe the 
consequences of such a delay on the outcome of the DNA repair assay. There 
was a substantial increase in cellular recovery in the samples that sat a day 
longer compared to those that did not (3.14 vs 2.14 million cells/ml blood, 
p<0.0001) (Fig. 5.4A). Additionally, there was a substantial decrease in the 
average DNA recovery in the samples that sat longer compared to those that did 
not (1.04 vs 1.51 µg/million cells, p=0.002) (Fig. 5.4B).  These changes in 
recovery did not have an effect on DNA repair, however. The average half-life of 
the samples that took an extra day to process was not significantly different than 
those isolated after being kept on ice one night.  The samples that did not have 
an extra day delay had an average half-life of 4.16 hours with a standard 
deviation of 1.80 hours, compared to those that did have an extra day delay, 
which had an average half-life of 4.27 hours with a standard deviation of 1.44 
hours (p=0.80) (Fig. 5.4C).    
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5.2.7 Impact of storage time and storage and isolation dates on NER 
efficiency 
After isolating the lymphocytes from the blood samples, the cells were 
stored in liquid nitrogen.  The duration of the storage varied from a few days to 
almost three years, as experimental parameters were still being established 
when the lymphocyte collection began.  Samples therefore remained in liquid 
nitrogen storage until the stimulation protocol was fully completed, and were 
removed in batches for stimulations.  Previous DRC studies using the host-cell 
reactivation assay have suggested that the length of time the lymphocytes are 
cryopreserved could potentially modulate DNA repair [260, 273], so the time 
between lymphocyte isolation and stimulation was compared to half-life of each 
individual in the study population to look for a possible relationship.  Half-life was 
not impacted by the length of lymphocyte storage in liquid nitrogen (Fig. 5.5A).  A 
linear regression analysis of the scatter plot produced an R2 value of 0.128 (p 
=0.113).  Additionally, we examined the chronology of our isolations and 
stimulations to determine if some factor, such as a change in the batch of some 
processing material, may have caused a temporal change in our repair assay, as 
temporal variation in DRC had been previously suggested [273].  Across three 
years of isolations and stimulations, there was little impact in half-life based on 
when the sample was isolated or when the sample was stimulated for repair (Fig. 
5.5B-C).  Linear regression analyses of the graphs of isolation date and 
stimulation date plotted against half-life produced R2 values of 0.0016 (p = 0.576) 
and 0.0147 (p = 0.089) respectively. 
109 
 
5.3 Discussion 
Measuring individual DNA repair capacity (DRC) from isolated 
lymphocytes in a human population as a means of estimating cancer risk was 
first proposed 25 years ago [258].  The classical methods employed to measure 
individual DRC from isolated lymphocytes have been the host-cell reactivation 
assay and variations on the comet assay [274-277].  Our findings indicate that 
DNA repair capacity can be measured using an alternative assay to those 
presently available, employing cellular machinery to repair DNA damage. The 
DNA repair assay utilized here is designed to monitor the removal of DNA lesions 
introduced by UV-C exposure.  These lesions are removed exclusively by the 
nucleotide excision repair pathway, making the assay a specific measure of NER 
efficiency.  We have reported here the successful implementation of this repair 
assay on a human population for the first time. 
We examined the impact of several factors that had the potential to 
confound our measurement of NER efficiency.  As this assay had not been 
implemented in a human population before, it was necessary to measure the 
reliability of the repair assay.  To that end, we tested recovery parameters, 
temporal fluctuation on the repair process, and multiple stimulations of the same 
samples to look at how well the half-life measure of NER efficiency performed.  
We observed that the processing time, stimulation and isolation dates, and time 
between stimulation and isolation did not contribute to a significant variation in 
NER efficiency, as measured by the repair assay endpoint, half-life.  Additionally, 
blood volume and lymphocyte recovery did not have an impact on half-life.  Blood 
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volumes as low as 5 ml provided NER efficiency measures that were no different 
than 15 ml samples. This is important as it provides us with an idea of how much 
biological material must be consumed in order to get a reliable measure of NER 
efficiency from an individual.   
The time required to process the samples after the blood was drawn did 
not significantly impact NER efficiency.  It did, however, have a significant impact 
on two other experimental parameters, cell recovery per volume of blood and 
DNA recovery per number of cells stimulated.  The cell recovery was increased 
and the DNA recovery was decreased as processing delay increased.  We 
observed that samples whose processing time was one day longer than the 
normal time had a higher incidence of red blood cell contamination in the buffy 
coat during lymphocyte isolation.  Based on the observation that samples with 
potential contaminating cells were difficult to stimulate, we concluded that DNA 
from nucleated cells present in the sample was causing the difficulty with our 
stimulation.  Not all samples that were delayed an extra day during the shipping 
process were affected in this manner, and those unaffected seemed to have no 
discernable difference in repair compared to samples shipped properly, but the 
increased incidence of a failure to stimulate among samples that did have 
extended shipping time highlights the importance of proper shipping time in order 
to maximize the success of the DNA repair assay. 
Our results here indicate that NER efficiency can be directly measured 
from isolated lymphocytes from blood samples, preferably when the isolation 
occurs within 24 hours of the blood draw.  This is a longer period of time than 
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most studies, as previous measures of DNA repair from isolated lymphocytes 
have typically drawn blood at the same location where lymphocytes are isolated 
and cryopreserved, or the shipping time has been kept to a minimum.  Our 
findings indicate that a study in which blood samples are provided remotely and 
shipped to a central location for processing can achieve a reproducible measure 
of repair.  
5.4 Conclusions 
The ability of our cells to remove DNA damage in a timely manner is 
paramount to survival.  The NER pathway responds to an array of environmental 
and endogenous mutagens, repairing damaged DNA and preventing cancer-
causing mutations from forming.  We observed a wide range in individual NER 
efficiencies within the study population.  Fluctuations in repair efficiency may 
provide an early indicator for cancer risk.  Those individuals with a low NER 
efficiency may be at a higher risk of failing to repair DNA damage, which could 
result in an increased risk of developing cancer.  
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Table 5.1 Repeated measurement of NER efficiency in isolated PBMCs  
 
 
Table 5.1 Lymphocytes from twelve individuals were stimulated two different 
times and DRC was measured for each stimulation.  Half-life values are the 
average of three repeated slot blots of the same DNA.  Half-life and standard 
error (SE) are both in units of hours.  P-value taken from a two-sided Student’s T-
test. 
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Figure 5.1 DNA repair assay performed on lymphocytes isolated from 
whole blood 
 
 
Fig 5.1 (A) The results of one slot blot from the DNA repair assay.  Equal 
amounts of DNA isolated from each indicated timepoint after irradiation are 
slotted in duplicate, and an antibody specific to 6-4 PPs is used to visualize 
removal of DNA damage over time.  (B) The percent 6-4 photoproducts removed 
are calculated from three repeats of the slot-blot per individual, with the average 
repair and standard error at each timepoint plotted on the graph.  (C) The percent 
repair values are converted into % 6-4 photoproducts remaining at each 
timepoint, and the average and standard error values are plotted as shown.  
From this data, an exponential decay regression analysis was performed to 
generate the half-life (and standard error) values shown. 
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Figure 5.2 The distribution of NER efficiency across the study population.  
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Fig 5.2 (A) A Histogram of half-life distribution across the entire population is 
shown, as well as the average and standard deviation of the population half-life.  
The NER efficiency of the study population has a predominantly Gaussian 
distribution but is skewed towards slower repair values (right tailed).  The 
Kolmogorov-Smirnov (KS) test for data normality indicates that the half-life 
values are not normally distributed (p < 0.0001).  (B) In order to produce a 
normally distributed data set, a natural log transformation of the data was 
performed, and a histogram of the natural log transformed data is shown, along 
with the average and standard deviation of the transformed half-life of the study 
population.  The KS normality test confirms that the natural log-transformed half-
life values are normally distributed (p = 0.3807) 
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Fig. 5.3 The impact of collection parameters on half-life. 
 
 
Fig 5.3 (A) A scatter plot of blood volume verses half-life shows a slight reduction 
in half-life with increasing sample volume, but the trend is not significant.  A linear 
regression analysis of the data produced an R2 value of 0.0148 (p =0.09). (B) A 
scatter plot of lymphocyte recovery verses half-life shows a slight increase in 
half-life with increasing lymphocyte recovery, but the trend is not significant.  A 
linear regression analysis of the data produced an R2 value of 0.018 (p =0.06).  
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Figure 5.4 The impact of processing delay on experimental parameters. 
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Fig 5.4 (A) A scatter plot of processing delay verses lymphocyte recovery shows 
a significant increase in cells recovered with increasing processing delay.  A 
linear regression analysis of the data produced an R2 value of 0.0859                 
(p =0.00003). (B) A scatter plot of processing delay verses DNA recovery 
indicates that higher delay times significantly reduce DNA recovery, perhaps as a 
result of an increase in non-lymphocyte cell contamination with increasing 
processing delay.  A linear regression analysis of the data produced an R2 value 
of 0.0555 (p = 0.0008). (C) A scatter plot of processing delay verses half-life 
shows that despite changing recovery parameters, the time delay between blood 
draw and lymphocyte isolation does not have any impact on half-life.  A linear 
regression analysis of the data produced an R2 value of 0.000011 (p = 0.963).  
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Figure 5.5 The impact of storage time and processing dates on half-life. 
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Fig 5.5 (A) A scatter plot of processing delay verses half-life shows that despite 
changing recovery parameters, the time delay between blood draw and 
lymphocyte isolation does not have any impact on half-life.  A linear regression 
analysis of the data produced an R2 value of 0.0128 (p = 0.113).  (B) A scatter 
plot of isolation date verses half-life shows no temporal effect on the repair 
endpoint.  A linear regression analysis of the data produced an R2 value of 
0.0016 (p =0.576). (C) A scatter plot of stimulation date verses half-life shows no 
significant change in half-life across the two year period in which stimulations 
were performed.  A linear regression analysis of the data produced an R2 value 
of 0.0147 (p = 0.089). 
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Supplemental Fig. 5.1 The impact of cancer treatment therapies on half-life. 
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Supplemental Fig. 5.1 (A) Lung cancer subjects were placed into groups based 
on whether or not they received a particular treatment – radiation therapy, 
chemotherapy, or surgery. Half-life values and standard errors were determined 
for each population and are shown.  (B) A subset lung cancer subjects were 
separated into groups of individuals who received a particular treatment and 
those who received no treatment.  Half-life values and standard errors are 
shown. (C) P-values were obtained by comparing individuals who did or did not 
receive a particular type of treatment (as shown in (A). (D) P-values were 
obtained by comparing individuals who received a particular treatment and those 
who received no treatment at all (as shown in (B)). 
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Chapter 6 
Variations in nucleotide excision repair efficiency in a human 
population 
6.1 Introduction 
Maintenance of genomic fidelity is critically important to the survival of 
living organisms.  DNA damage, from endogenous and exogenous sources, is a 
constant, huge burden on the cell.  If left unrepaired, this damage can result in 
DNA mutations, leading to an increase in cancer risk, or the damage can trigger 
apoptotic cell death, an event associated with organismal aging.  In humans, 
several multi-protein pathways contribute to the maintenance of genomic fidelity, 
including the nucleotide excision repair (NER) pathway [213].  The NER pathway 
is responsible for recognizing and removing a wide variety of structurally diverse 
DNA lesions.  Substrates for NER include adducts generated by metabolites of 
chemical carcinogens such as polycyclic aromatic hydrocarbons in tobacco 
smoke, UV-induced photoproducts, and platinum adducts formed by the 
chemotherapeutic agent cisplatin [19].  
In humans, more than twenty different proteins are involved in the NER 
pathway.   These proteins include the XPA-G factors that are singly defective in 
seven corresponding complementation groups of the human disorder Xeroderma 
Pigmentosum (XP) [25].  The tumor suppressor factor p53 also impacts NER 
efficiency, likely through transcriptional regulation of the XPC and DDB2 gene 
products, both of which are DNA damage recognition proteins [20, 21, 114, 115]. 
The NER pathway is comprised of two sub-pathways that differ in their 
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mechanism of damage recognition: global genomic NER (GG-NER) which 
recognizes and removes DNA damage from anywhere in the genome and 
transcription-coupled NER (TC-NER) which selectively removes damage from 
the transcribed strands of actively transcribed genes.  In GG-NER, DNA damage 
recognition is accomplished by XPC, which recognizes helically distorting lesions 
and is stabilized by its binding partners RAD23B, and CENTRIN2 [26, 27].  
Additionally DDB2 assists XPC in recognition of certain DNA photolesions such 
as the cyclobutane pyrimidine dimer [142], which is not as well recognized as the 
6-4 photoproduct (6-4 PP) by XPC [34].  In TC-NER, damage is recognized by 
the stalling of the RNA polymerase complex at the site of damage during 
transcription (reviewed in [24]).  After the DNA damage recognition step, many of 
the subsequent steps are the same for GG-NER and TC-NER. The helicase 
activities of TFIIH produce additional unwinding of DNA where upon the 
endonuclease activities of the XPF/ERCC1 complex and XPG produce single-
strand incisions flanking the damaged site.  The original integrity of the DNA is 
restored after an approximately 30 nucleotide region of DNA containing the 
lesion is removed, and the gap is filled by pol δ or pol ε, using the undamaged 
strand as a template (reviewed in [25]).  
Genetic deficiencies in NER are the origins of rare human disorders 
including Xeroderma Pigmentosum (XP), Cockayne Syndrome, and 
Trichothiodystrophy [39].  Of these, XP is characterized by dramatically 
increased skin cancer rates as well as increased internal neoplasms [40, 211, 
278].  While XP is rather uncommon, polymorphisms in NER genes can have 
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much greater incidences [257, 279, 280]. Several of these polymorphisms have 
been associated with increased risk of developing cancer, including colorectal 
[281], prostate [282], liver [283], esophagus [284], lung [285], and skin cancers 
[279, 286].  In addition, the expression levels of several NER proteins have been 
associated with increased cancer risk [249, 287]. 
As these studies show, there are many factors controlling the proteins 
involved in NER that have the potential to contribute to cancer risk.  As such, a 
functional analysis of population variation in DNA repair capacity may be of 
greater value in predicting cancer risk. To this end, several studies have 
employed functional assays to investigate the variation in DNA repair within a 
human population.   The two most common methods of measuring population 
distribution of DNA repair have been using the Comet assay [274, 277, 288] and 
the host cell reactivation (HCR) assay [258, 259, 269, 289].  The Comet assay 
relies on measuring the presence of DNA strand breaks as an indicator of DNA 
repair.  Combining a damage source with an endonuclease specific to an adduct 
generated by that, such as the use of bacterial T4 endonuclease V to cleave at 
sites of CPDs, allows the Comet assay to measure the repair of a specific GG-
NER substrate [290]. The HCR assay, on the other hand, measures repair of a 
transcriptionally active gene, typically on a transfected plasmid, via detection of 
the gene product, and as a result the HCR assay is actually measuring the TC-
NER subpathway of NER. 
We have employed a modified immunoblot assay to measure NER 
efficiency in isolated peripheral blood mononuclear cells (PBMCs) in a human 
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population.  The repair assay measures the removal of a UV-induced 
photolesion, the 6-4 photoproduct.  The 6-4 photoproduct (6-4 PP) and 
cyclobutane pyrimidine dimer (CPD) DNA adducts, produced by UV light, are 
model substrates for measuring NER activity as they are rapidly generated by a 
brief exposure to UV light and are repaired exclusively by NER in humans [25].  
6-4 PPs are repaired much more quickly than CPDs, likely due to the degree with 
which the two lesions are recognized by NER [291], and as such we chose to 
measure 6-4 PP removal in individuals to maximize detection of variations in 
NER efficiency.  
We explored the efficiency of NER in individuals residing in the 
Appalachian region of Kentucky in preparation for a larger case-control study 
investigating lung cancer incidence in the region.  Appalachian Kentucky has 
some of the highest cancer rates in the nation, including a lung cancer rate 
(109.2 per 100,000, http://cancer-rates.info/ky/index.php) that is almost double the 
national average (59.4 in 100,000, https://nccd.cdc.gov/uscs/toptencancers.aspx).  We 
observed an age-dependent reduction in NER efficiency in the study population, 
and a slight tendency for females to have higher NER efficiencies than males.  
We also observed that the age-dependent reduction of NER efficiency can be 
modulated by smoking status.  These findings will aid in implementing this repair 
assay in future studies investigating the relationship between DNA repair and 
cancer susceptibility. 
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6.2 Results 
6.2.1 Statistical Analysis 
The results of three slot blots obtained from a single biological repair 
experiment were averaged and used to calculate the NER half-life value for each 
individual. When the percentage of adducts remaining at each time point was 
plotted using a log scale, the individual plots were largely linear indicating that 
the data exhibit an exponential decay pattern. Therefore, we performed an 
exponential decay regression analysis of the averaged values for the percentage 
of adducts remaining that we obtained in each experiment using Sigma Plot and 
the equation:𝑓𝑓(𝑥𝑥) = 𝐴𝐴𝑒𝑒−𝑏𝑏𝑏𝑏.  In this equation, 𝑓𝑓(𝑥𝑥) is the percentage of 6-4 PPs 
remaining at time 𝑥𝑥.  Setting 𝑓𝑓(𝑥𝑥) equal to 50% and solving for 𝑥𝑥, which is the 
time taken to remove 50% of the 6-4 PPs, produces the equation: 𝑥𝑥 = -ln(50/A)/𝑏𝑏.  
The regression analysis provided the exponential decay variables (A and b) 
necessary to calculate the half-life value.   
The difference in average NER efficiency between age groups was 
evaluated by a 1-way ANOVA trend analysis and the difference in average NER 
efficiency between groups separated by smoking status or gender were evaluated 
by a 1-way student’s T-test.  When comparing NER efficiency and subject age as 
a continuous variable, a linear regression analysis was performed on the data and 
the coefficient of determination (R2) obtained from that regression analysis was 
used to obtain the Pearson correlation coefficient (R).  A multiple comparison 
analysis was performed between age, gender, and smoking and their combined 
effects on NER efficiency.  Lastly, an interaction effect was examined evaluating 
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the impact of smoking and gender on the effect of subject age on NER efficiency.  
In all cases, the threshold for significance was P < 0.05.  All statistical analyses 
were performed using the Graph Pad Prism 6 and SAS 9.3 software. 
6.2.2 Study Population 
Individuals were identified from Kentucky voter registration records of the 
5th Congressional District of Kentucky located within the region defined as 
Appalachian Kentucky.  All participants were required to be over the age of 17 
years and have no previous diagnosis of cancer, with the exception of stage I or 
stage II non-melanoma skin cancer.  Participants were required to have a working 
phone and be willing to consent to an in-person interview held in at their residence 
without the use of an interpreter.  A detailed questionnaire which included 
questions about smoking history, work history, and medical history was 
administered by an employee of Kentucky Homeplace, who also drew blood 
samples.  The blood samples were transferred into sodium heparin-coated tubes, 
placed on ice and shipped overnight by courier to the Biospecimen and Tissue 
Procurement Shared Research Facility (BSTP SRF) at the University of Kentucky 
and then distributed to Dr. Mellon’s laboratory for the isolation of PBMCs. 
6.2.3 Study population demographics 
 Subject recruitment numbers for this study as well as several population 
demographics are shown in Table 6.1. The average age of the study population, 
61.7 years, is high due to the frequency matching of these individuals to a group 
of lung cancer patients for a larger case-control study.  There are an equal number 
of males and females in the study population.  Study participants were assigned 
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to one of three smoking groups based on a questionnaire that asked whether they 
were current smokers, former smokers (a history of smoking, but no smoking in 
the last 6 months), or never smokers (less than 100 cigarettes in their lifetime).   
Half of the participants reported being never smokers (n = 79, 50.6%), while the 
other half were either current (n= 26, 16.7%) or former (n= 51, 32.7 %) smokers.  
This distribution of cigarette usage in our study population is consistent with 
recently reported data for smoking status and smoking history among individuals 
residing in Appalachian Kentucky,  the geographical area in which all of our study 
participants lived [12]. 
6.2.4 Measurement and distribution of NER efficiency in the study 
population 
 We measured the efficiency of NER in each person within our study 
population using PBMCs isolated from individual blood samples and an immuno-
slot blot method to quantify the introduction and removal of 6-4 PPs produced by 
irradiation with UV light. We chose to utilize the removal of 6-4 PPs from live cells 
as a representation of NER efficiency in people because a number of 
biochemical, cellular and animal studies have shown that 6-4 PPs are model 
substrates for NER [292-296].  We chose PBMCs to study because acquiring 
blood from donors is relatively less invasive than acquiring most solid tissue 
samples. In addition, most assays that measure NER function/activity require 
viable cells but they have not been successful when applied to solid tissue 
samples. The time course of 0 – 4 h was established in preliminary studies using 
blood samples obtained from healthy volunteers at the University of Kentucky 
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who removed most 6-4 PPs during this time period after treatment of PBMCs 
with 20 J/m2 UV-C. The dose of 20 J/m2 was chosen to achieve a strong 
antibody-dependent chemiluminescence signal well above background levels 
using 100 ng of DNA per slot and to also achieve a strong signal since PBMCs 
are grown in suspension rather than as a monolayer which necessitated 
irradiating them in the presence of growth medium.  
Representative immuno-slot blots illustrating the kinetics and extent of 
repair in three different subjects are shown (Fig. 6.1A). For each subject, three 
independent slot-blots were performed and the results were averaged to 
calculate the percentage of 6-4 PPs removed at each time point (Fig. 6.1B). 
Since our goal was to compare the efficiency of NER among all individuals in our 
study, we chose to use the results obtained from all 3 repair time points to 
calculate a single value for lesion half-life; the time it took for each individual to 
remove 50% of the 6-4 PPs introduced into the DNA of their PBMCs. To achieve 
this, the percentage of 6-4 PPs remaining at each time point was calculated and 
plotted using a logarithmic y-axis. This produced a linear response (Fig. 6.1C) 
and confirmed that the data fit an exponential decay model.  An exponential 
decay regression analysis was performed on the data as described in the 
methods section.  The half-lives for the individuals shown ranged from 1.57 h to 
3.45 h (Fig. 6.1C). This analysis was performed on 156 subjects and a histogram 
of these results illustrates the range and the distribution of NER efficiency across 
the population (Fig. 6.2A).  The population had an average half-life of 4.24 h, with 
a standard deviation of 1.70 h. Small half-live values indicate faster NER while 
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larger half-life values indicate slower NER. The half-life values ranged from the 
fastest, 1.52 h, to the slowest, 10.71 h. These results clearly show that the 
efficiency of NER can significantly differ among different individuals. It is unlikely 
that differences in NER efficiency can be attributed to differences in the 
introduction of UV damage. Identical conditions were followed for the irradiation 
of all samples and the intensity of the slot-blot band for the 0 h time point 
provided an indication of the uniformity of the introduction of damage across 
samples.  
The distribution of half-lives across this population shows a largely 
Gaussian distribution with some skewing towards the slower values, as expected 
given the nature of the repair assay.  Proficient repair values would be clustered 
around a peak value, and deficiencies in repair would produce larger half-life 
vaues and generate a right-skewed tail. According to the Kolmogorov-Smirnov 
(KS) test for a normal (Gaussian) distribution, the half-life values are not 
completely normally distributed (p < 0.01). The null hypothesis of the KS test 
states that the data are normally distributed, and thus a “significant” p-value 
means the data are not normally distributed.  Certain statistical analyses such as 
ANOVA and T-tests require (assume) a Gaussian distribution so we performed a 
natural-log transformation of the data and tested for normality. This is a common 
approach to normalize a slightly skewed distribution. The resulting distribution is 
normal (p > 0.15) as evaluated by the KS test (Fig. 6.2B). We performed several 
comparisons of NER efficiency between subpopulations using either the 
untransformed or transformed data sets and the results were similar regarding 
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trends and significance.  Hence, we chose to present the analysis of the non-
transformed data set in subsequent figures and all tables since a half-life value 
represented in hours rather than the natural-log of the hours is biologically more 
relevant.  
6.2.5 The efficiency of NER is reduced with increasing subject age 
 We investigated the relationship between NER efficiency and the age of 
each individual.  Initially, the study population was separated into three different 
age groups and the average half-life obtained from each age group was 
compared (Fig 6.3a).  NER efficiency slowed with increasing subject age when 
subjects were stratified into the three age groups shown, as indicated by an 
increase in half-life across these age groups.  A one-way ANOVA analysis 
examining the trend of increasing half-life with age showed that this trend was 
significant (p = 0.0023). Additionally, we examined the relationship between 
subject age and NER efficiency when age was evaluated continuously instead of 
in discrete groups.  A graph of the half-life value plotted against age for each 
individual in the study is shown (Fig 6.3b).  A linear regression analysis of this 
data produced a coefficient of determination (R2) value of 0.655.  The Pearson 
score (R = .2559) indicates a significant relationship between subject age and 
half-life (p = 0.0013) using the continuous measurement of subject age. 
 Factors such as lymphocyte and DNA recovery were also evaluated for 
their potential to modulate the observed effect of subject age on NER efficiency 
and were determined to have minimal impact (data not shown, but similar work 
was done in chapter 5 and a similar conclusion was drawn for that population). 
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6.2.6 The relationship between NER efficiency and other population 
demographics 
We investigated whether the smoking status of each individual could 
influence their efficiency of NER.  There is some limited evidence that current 
smokers may have faster repair than former or never smokers [289, 297, 298], 
although these experiments utilized the HCR assay and therefore measured TC-
NER.  A graph of the average half-lives and their standard deviations found for 
current, former and never smokers is shown (Fig 6.4a).  The current smoking 
population has a faster half-life (3.83 h) than the former (4.37 h) and never 
smoking (4.28 h) populations, although the difference is not statistically 
significant (p = 0.0914).  However, the group of current smokers also has a lower 
average age than the other two groups, and since we have found that subject 
age influences that efficiency of NER, the faster NER found in current smokers is 
less pronounced after accounting for age (See below and Table 6.1).  As the 
difference in smoking groups was most pronounced between current smokers 
and “non-current” that was the comparison that was presented.  Comparisons 
between individual groups, including current vs former and current vs never have 
even higher p-values than those between current and non-current smokers as a 
result of diminished sample sizes. 
The impact of gender on NER efficiency was also investigated.  Previous 
studies have suggested slight increases in DNA repair capacity in males 
compared with females [273, 299].  In our study, however, females had a 
somewhat faster NER efficiency than males, as indicated by an average half-life 
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of 4.12 ± 1.66 h for females compared to 4.35 ± 1.74 h for males (Fig 6.4b).  This 
difference was not statistically significant (p = 0.2029) using a 1-way student’s T-
test. However, this trend was present in every subpopulation examined; females 
had a faster NER efficiency than males in all three age groups and all three 
smoking groups, although these differences were not statistically significant, 
perhaps due to small sample sizes (Table 2).   
6.2.7 The reduction in NER efficiency with increasing subject age is not 
seen in all subpopulations 
As with the total population, the male and female populations both show a 
trend of decreasing NER efficiency (increasing half-life) with increasing subject 
age (Fig 6.5a and 6.5b), and the trend is significant in both males and females.  
The strength of the relationship was stronger in the male population than the 
female population, as evident in the p-values for age associated decline in NER 
efficiency in males (p = 0.013) and females (p = 0.038).  However, separating the 
study participants by smoking status reveals that only current and former 
smokers show an age-dependent decline in NER efficiency (Fig 6.6a and 6.6b 
respectively) while non-smokers show no such trend (Fig 6.6c).  Supplemental 
table 6.1 contains the R2 values and p-values derived from linear regression 
analysis of graphs of the relationship between age and NER efficiency in each 
population. Since non-smokers do not show an age-dependent decline in NER 
efficiency, the smoking status of individuals (in addition to their age) must be 
accounted for when drawing meaningful comparisons of NER efficiencies 
between groups of individuals, such as in case-control studies. 
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6.2.8 Multivariable analysis confirms efficiency of NER is effected by 
subject age 
 We performed a multivariable regression analysis to determine which 
factors were significant modulators of NER efficiency when examined together.  
As indicated in Table 1 in the “adjusted p-value column”, subject age remains the 
only significant factor effecting NER efficiency when age, gender, and smoking 
status are all considered (p = 0.0138).  The analysis indicates that neither gender 
(p = 0.2005) nor smoking (p = 0.3987) are significant contributors to variation in 
NER efficiency.  The multivariable regression analysis did not alter the 
significance of age or gender on NER efficiency, but the p-value for smoking 
(which compared current smokers to former and nonsmokers) changed from 
0.0914 to 0.3987, likely due to the large difference in ages between the smoking 
groups (current smokers were considerably younger than former/never smokers).  
Since subject age had a large effect on NER efficiency, the difference in ages 
between the smoking groups was ultimately responsible for most of the 
difference in NER efficiency between smoking groups.  As the male and female 
populations had very similar ages, the multivariable regression analysis did not 
change the p-value for the effect of gender on NER efficiency.  Finally, an 
interaction effect was incorporated into the multivariable regression analysis to 
evaluate the impact of smoking status and gender on the observed age effect on 
NER efficiency.  Smoking status (p = 0.0226) had a significant impact on the 
observed age-dependent effect on NER efficiency, while gender (p > 0.80) did 
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not.  This finding is consistent with our observation that both the male and female 
population showed a strong reduction in NER efficiency with increasing age. 
 We also examined the relationship between lymphocyte and DNA 
recovery and the effect of subject age on NER efficiency.  Similar to the results 
presented in chapter 5, these two collection parameters did not have any 
significant impact on the subject age-dependent modulation of NER efficiency. 
6.3 Discussion 
Nucleotide Excision Repair is a critical pathway involved in removal of 
DNA damage that would otherwise promote mutations and increase cancer risk.  
We have established that this assay can reproducibly measure individual NER 
efficiency, as well as measure across a large range of values in a population.  
NER efficiency was measured in a rural population in Appalachian Kentucky, an 
area that suffers high cancer rates, poor overall health, and limited access to 
healthcare.  The objectives of the study were to determine how NER efficiency 
was distributed across a population when measured using this assay and 
establish whether this repair assay could measure differences in DNA repair 
between individuals or groups of individuals in a population. The study population 
exhibited a wide range of NER efficiencies, with almost an order of magnitude 
separating the half-lives of the fastest and slowest repairing individuals.  The 
range of repair values is consistent with HCR ranges, which also can exhibit an 
order of magnitude difference between the smallest and largest values [300].  We 
observed a significant decline in DNA repair specific to the NER pathway with 
increasing age of study subjects, both male and female. We also found that 
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smoking status impacts the age-dependent decline in NER efficiency. This 
information will guide further implementation of the repair assay for use in 
measuring NER efficiency as a potential biomarker of cancer susceptibility. 
In addition to contributing to cancer risk, defective DNA repair may have a 
role in the process of aging.  Aging can be viewed as a reduction in biological 
functions that occurs with time as a result of an accumulation of somatic DNA 
damage [301, 302].  This is due in part to an increase in genomic instability  
(reviewed in [303]).  There are two primary factors that regulate genomic stability; 
the rate of DNA damage induction and the efficiency of DNA repair.  A reduction 
in DNA repair would promote an increase in genomic instability, promoting 
cellular and potentially organismal aging. 
Genetic deficiencies in NER lead to increases in an aging phenotype, 
including premature cell death and reduced lifespans, in both humans [42, 213, 
304] and mice [305, 306].  These studies use repair deficient systems and thus 
show the consequences of impaired NER, but they do not provide information on 
the relationship between normal DNA repair and aging.  Several studies have 
investigated the relationship between proficient DNA repair and aging (reviewed 
in [307]).   Early studies using the unscheduled DNA synthesis (UDS) assay 
found that UV-induced DNA damage was repaired more slowly with increasing 
age in rats [308] and more slowly in later passages of WI-38 human lung cells 
compared to earlier passages [309]. A decline in NER efficiency, as measured by 
reduced removal of UV-induced photolesions, with increasing donor age was 
observed in cultured human dermal fibroblasts [310].   
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A number of studies have explored the relationship between DNA repair 
and aging in isolated lymphocytes in a human population using the host-cell 
reactivation assay (HCR). However, as stated above, this assay measures TC-
NER, and the results of these studies have been quite varied.  DNA repair 
capacity (DRC) was reduced with increasing subject age in a study of lung 
cancer patients [260].  In contrast, other studies have shown that DRC 
decreased with age in healthy individuals but increased with age in cancer 
patients [311, 312].  DRC has also decreased with increasing subject age 
regardless of cancer status in both groups significantly [259], or only significantly 
in the control population [313-315].  Some studies have reported that age did not 
contribute significantly to DRC in either the case or control populations [273, 
316], and DRC has even remained unchanged in controls while increasing with 
age in cancer patients [299].   
The previous findings from human population studies suggest that the 
current understanding of the relationship between DNA repair capacity and 
subject age from isolated lymphocytes in a human population is not complete.  
We saw a very strong influence of age on NER efficiency, and we also observed 
that this effect was modulated by smoking status (as indicated by the significance 
of the interaction variable of smoking and age on NER).  It is possible that this 
interaction may explain some of the disparities in the age effect on DNA repair 
seen in these studies – if smoking status is not uniform across age groups it may 
obscure the effect of subject age on DNA repair.   
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Our findings indicate that subject age must be properly matched when 
comparing NER efficiency between populations, as when exploring the effect of 
DNA repair on cancer susceptibility.  Additionally, while smoking status did not 
significantly alter NER efficiency, it had a significant impact on the age-
dependent decline in NER efficiency. As a result, we propose that smoking status 
should also be consistent both between study populations and across age 
groups within the same population in order to most accurately measure 
differences in NER efficiency between populations.  
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Table 6.1 Factors affecting NER efficiency 
 
 
Table 6.1 Demographic information and NER efficiency are provided for the 
indicated groups in the study population.  P-values from comparisons of half-lives 
between different subpopulations are shown. For comparing half-life values 
across the three age groups, the p-value was obtained from a 1-way ANOVA 
trend analysis.  For comparing half-life values in groups based on smoking status 
or gender, the p-value was obtained from a 1-way Student’s T-test. The adjusted 
p-value is the result of a multivariable regression analysis that factored age, 
smoking status, and gender.  The interaction effect p-value was derived from the 
multivariable regression analysis and indicates whether the indicated variable 
had a significant influence on the observed effect of subject age on NER 
efficiency. 
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Table 6.2 Influence of gender on NER efficiency in various study 
populations. 
 
 
Table 6.2 A comparison of NER efficiency between males and females in 
different groups of the study population. Females tend to repair faster than males 
across all populations measured, but the difference is not significant.   
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Figure 6.1 DNA repair assay performed on lymphocytes isolated from three 
different subjects
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Figure 6.1 (A) A slot-blot from each of three individuals in the study is shown.  
(B) The percent 6-4 photoproducts removed are calculated from three repeats of 
the slot-blot per individual, with the average repair and standard error at each 
timepoint plotted on the graph.  (C) The percent repair values are converted into 
% 6-4 photoproducts remaining at each timepoint, and the average and standard 
error values are plotted as shown.  From this data, an exponential decay 
regression analysis was performed to generate the half-life (and standard error) 
values shown for each individual. 
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Figure 6.2 The distribution of NER efficiency across the study population 
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Figure 6.2 (A) A Histogram of half-life distribution across the entire population is 
shown, as well as the average and standard deviation of the population half-life.  
The study population’s NER efficiency has a mostly Gaussian distribution but is 
slightly skewed towards slower repair values.  The Kolmogorov-Smirnov (KS) 
normality test indicates that the half-life values are not normally distributed (p < 
0.01).  (B) In order to produce a normally distributed data set, a natural log 
transformation of the data was performed, and a histogram of the natural log 
transformed data is shown, along with the average and standard deviation of the 
transformed half-life of the study population.  The KS normality test confirms that 
the natural log-transformed half-life values are normally distributed (p > 0.15) 
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Figure 6.3 NER efficiency is reduced with increasing subject age 
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Figure 6.3 (A) A graph of the average half-life and standard error for the 
population separated into three age groups shows an increase in half-life with 
increasing subject age. A 1-way ANOVA trend analysis for increasing half-life 
produced a p-value of 0.0023. (B) A scatter plot of the half-life vs subject age of 
each individual in the study also shows an increase in half-life with increasing 
subject age.  A linear regression analysis of the data produced an R2 value of 
0.0655 (p = 0.0013) 
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Figure 6.4 The effect of smoking status and gender on NER efficiency 
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Figure. 6.4 (A) The effect of smoking status on NER efficiency.  The average 
half-life and standard error from each of the three smoking groups in the study 
are plotted on the graph.  The current smokers have a faster NER efficiency 
compared to the other smoking groups, but the difference is not significant (p = 
0.0914). (B) The effect of gender on NER efficiency. The average half-life and 
standard error of females and males in the study are plotted on the graph.  
Female subjects have a moderately faster NER efficiency than males, but this 
difference is not statistically significant (p = 0.2029). 
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Figure 6.5 NER efficiency decreases with subject age in both genders in the 
study population 
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Figure 6.5 Scatter plots of the distribution of half-life compared to subject age for 
male (A) and female (B) subjects in the study population are shown.  Regression 
analysis of the scatter plots of subject age verses half-life provided R2 values of 
0.0792 (p = 0.013) and 0.0554 (p = 0.038) for males and females respectively, 
indicating a significant relationship between age and NER efficiency in both 
populations. 
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Figure 6.6 The age-dependent decline in NER efficiency depends on 
smoking status 
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Figure 6.6 Scatter plots of the distribution of half-life compared to subject age for 
current (A), former (B), and never smoker (C) subjects in the study population are 
shown.  Regression analysis of the scatter plots of subject age verses half-life 
provided R2 values for the current and former smoking populations of 0.4759 (p = 
0.0001) and 0.1059 (p = 0.02) respectively, indicating a significant relationship 
between age and NER efficiency in both populations.  The regression analysis 
performed on the non-smoking population, however, produced an R2 value of 
0.0026 (p = 0.655), indicating there is no decline in NER efficiency with 
increasing subject age in the non-smoking population. 
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Supplemental Table 6.1 Strength of association between subject age and 
NER efficiency in different study populations 
 
S. Table 6.1 A linear regression analysis of subject age and NER efficiency was 
performed for the study population as well as several subpopulations in the 
study.  Both genders overall show a strong age effect on NER efficiency, as do 
the current and former smoking populations, but the males and females in the 
never-smoking population do not.  
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Chapter 7 
Unanswered questions, a case-control study, and a future 
direction for the NER functional assay 
7.1 Did reduced XPC expression impair NER? 
 I have presented my findings indicating that the efficiency of the 
Nucleotide Excision Repair pathway can be impacted by environmental factors 
such as tobacco smoking and arsenic and by epidemiological factors like age 
and possibly even gender.  The variations in NER efficiency observed in the 
previous chapters may increase the risk of cancer development. Numerous 
reports indicate that defective NER [40, 211, 278], reduction in expression of 
NER factors [249, 287], polymorphisms in NER genes [279, 281, 283-286], and 
variations in (TC) NER efficiency within a population [259, 312, 317] all contribute 
to cancer risk.   
We observed a reduction of XPC protein and RNA levels that was 
concurrent with a reduction in NER efficiency in cells treated with either CSC or 
arsenic.  One important question remains unanswered: Is the inhibition of NER 
produced by CSC or arsenic a consequence of the reduction of XPC?  Loss of 
XPC eliminates functional GG-NER [245, 318], and evidence suggests that 
reduction in expression may also inhibit repair of UV-induced 6-4 PPs [245] and 
ultimately increase cancer risk [47, 152], but we need a clear demonstration that 
this occurred in the cell lines that were tested.   
 There are at least two experimental systems that could be implemented to 
test the hypothesis that NER function was inhibited in the cell lines examined as 
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a consequence of XPC inhibition.  NER function could be measured in cells 
where XPC is artificially reduced in the absence of CSC or arsenic.  Small 
interfering RNA (siRNA) specific to XPC can knock down XPC expression [151].  
Stable transfection of the siRNA with an inducible promoter could be used to 
reduce the level of XPC to a level that is similar to what was observed in 
treatments of CSC or arsenic.  If reducing XPC in this manner produces a similar 
reduction in the removal of the photolesions we studied in the presence of CSC 
or arsenic, then the hypothesis would be supported.   
 The shortfall of this experiment, modulating XPC levels in the absence of 
the chemicals responsible for the observed reductions of XPC, is that any 
additional mechanisms of NER inhibition that CSC/arsenic may have employed 
that we have not yet quantified would be lost.  Therefore, if reducing XPC levels 
in the cell lines examined does not inhibit NER efficiency in the same manner 
that CSC/arsenic did, we are left not knowing whether this is because the XPC 
reduction was unrelated to repair inhibition or simply one of multiple changes the 
chemicals produced that combined to inhibit NER. 
Alternatively, overexpressing XPC as a means to protect the cell from the 
inhibitory effects of CSC or arsenic on NER would also provide evidence that 
XPC levels are responsible for the inhibition of NER seen in the treated cells.  
This experiment runs up against the issue of XPC toxicity, however.  As indicated 
in chapter 3, XPC is a highly regulated protein that has considerable post-
transcriptional modifications, including ubiquitylation.  Maintaining low levels of 
XPC is important, as XPC actively scans chromosomes looking for DNA damage.  
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Overexpression of XPC and its binding partner HR23B produced significant 
toxicity, likely by interfering with DNA metabolism by binding to a wide range of 
DNA structures [162].  Overexpressing XPC sensitizes p53-deficient cells to DNA 
damage-induced apoptosis [319], which may be a useful tool in combatting 
therapy resistant tumors, but it complicates the repair assay by potentially 
exaggerating the apoptotic effect of the DNA damage-inducing UV.  Additionally, 
a conditional, ubiquitous oxerpression of mus210, an XPC homolog, reduced 
average lifespan in fruit flies by almost 50% [320]. Therefore, overexpressing 
XPC in a cell containing endogenous XPC poses some challenges.  
7.2 XPC expression as a biomarker for cancer risk 
After determining that NER function and XPC expression could be 
impacted by CSC and arsenic, both known human lung carcinogens, we 
explored the hypothesis that XPC expression in human lung tissue may be a 
biomarker for cancer risk.  We proposed that XPC expression may be reduced in 
lung cancer tissue, relative to non-neoplastic adjacent tissue, and this reduction 
could be a driving force behind the lung carcinogenesis.  XPC expression level 
reduction could be a result of exposure to environmental agents like tobacco 
smoke or arsenic, similar to what was observed in our cell culture studies. 
Alternatively, XPC levels may be impacted by a mutation or an epigenetic 
change that results in reduced expression of XPC, reducing the ability of the 
NER pathway to function and perhaps ultimately driving the formation of the 
cancer.  Using immunohistochemistry, lung tissue samples acquired from 
biopsies of lung cancer patients were stained for XPC protein.  In a small pilot 
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study, nuclear XPC content was reduced in cancer tissue relative to non-
neoplastic adjacent tissue in the same slide.  However, we were unable to 
replicate our initial findings, and as such we could not draw any conclusions 
regarding the relationship between XPC expression and lung cancer.   
7.3 A more complete biomarker of cancer susceptibility 
Using the protein level of a repair gene such as XPC as a biomarker for 
cancer risk would be more easily accomplished from a bio-specimen that is more 
easily obtained, such as blood.  However, it would be prudent to establish a few 
other things first.  As the cancer risk associated with variations in protein 
expression of certain NER factors has produced inconclusive results thus far 
(see chapter 5), it may be more productive to evaluate the relationship between 
the efficiency of the NER pathway in cells isolated from blood and cancer risk 
first, and then look for a relationship between this efficiency and expression 
levels of certain proteins like XPC.  As an assay that measures NER efficiency is 
more involved than a simple expression study, it is less feasible to use the 
efficiency of NER as a predictor of cancer risk in a high-throughput fashion.  
However, it is critical that the correlation between NER efficiency and cancer risk 
be established as well as a strong relationship between, for example, XPC 
expression and NER efficiency, as this increases the strength of association 
between XPC expression (a more easily measured value than NER efficiency) 
and cancer risk.  
With that in mind, we participated in a large scale case-control study 
designed to investigate the causes of the large incidence of lung cancer in 
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Appalachian Kentucky.  Several investigators were involved in the study, and 
several hypotheses were tested to determine what was responsible for this 
cancer incidence.  Previous work done by members of the group had determined 
that, even though smoking rates are higher in Appalachian Kentucky than the 
rest of the state, several geographical areas had lung cancer incidences higher 
than the state average after adjusting for smoking [14].  At the time of this writing, 
the analyses performed by the other investigators are not complete, and as such 
I will not include their findings.   
Based on our findings from cell culture experiments that the carcinogenic 
chemicals CSC and arsenic inhibited NER efficiency as indicated in chapters 3 
and 4, we hypothesized that variations in NER efficiency between individuals 
could be a risk factor for cancer development.  The study was designed to 
provide blood samples from lung cancer subjects and age/gender matched 
control subjects.  Lymphocytes would be isolated from the blood samples and a 
repair assay would be performed.  Unfortunately, the number of lung cancer 
cases that were evaluated (42) was insufficient to produce the power necessary 
to draw any conclusions about potential differences in repair between the cancer 
and control groups.  Additionally, as we explored the variables that could 
potentially impact NER efficiency, we observed that age, smoking, and gender all 
had a role to play in determining individual NER efficiency (as discussed in 
chapter 6).  Since the study was not designed to have equal representation of 
smokers between cases and controls, the power of the study was even further 
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reduced, as comparing cases and controls after adjusting for smoking status 
reduced the sample sizes even further.  
Instead, we chose to report the findings of the population distribution of 
NER efficiency from the control group only, drawing inferences as to how a case-
control study should be designed in the future.  The study was designed to match 
lung cancer case and cancer-free control subjects on the basis of age and 
gender.  It did not require that they be smoking matched.  The results of our 
study indicate that the different smoking groups did not have statistically different 
average half-lives.  However, the observed effect of age and NER efficiency was 
modulated by smoking.  This means that an appropriate study design should 
include an even distributions of smokers between the cases and controls.  It also 
means that smoking incidence should also be evenly distributed across the range 
of subject ages for both cases and controls, as doing otherwise would produce 
an uneven effect of subject age on NER efficiency between the populations.  To 
our knowledge, no such adjustment has been made in any population studies 
that evaluate DNA repair from human lymphocytes. 
Even though we did not have a sufficient lung cancer subject sample size 
to properly compare cases and controls in our Appalachian Kentucky study, we 
did analyze NER efficiency in 42 lung cancer subjects.  One of our most 
significant findings in the control population, that NER efficiency was significantly 
reduced with increasing subject age (Figure 6.3), was not significant in the case 
population (Figure 7.1) or any of the subpopulations (males, females, current or 
former smokers).  This could be a consequence of selection bias – if reduced 
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NER efficiency is indeed a risk factor for the development of lung cancer, then 
lung cancer patients may not show a reduction in NER efficiency with increasing 
subject age, as the younger population is already presenting a reduction in NER 
efficiency.  If that is the case, then the age-dependent reduction in NER 
efficiency seen in the control population could be absent in the case population. 
The observation that the lung cancer population did not show a reduction 
with NER efficiency with increasing age suggests that comparisons between 
cases and controls may be more meaningful at lower age groups, before the 
control population experiences an age dependent reduction in NER efficiency.   
Indeed, the younger case population (individuals under 50 years old) had a 
slower NER efficiency than the younger control population, but the difference 
was not significant (Figure 7.2).  As expected, since the case population does not 
show a reduction in NER efficiency with age, the NER efficiency in the case 
population is actually greater than the control population in the second and third 
age groups (although it is only significant in the middle age group).  An important 
observation was that all of the lung cancer cases under 50 years old were current 
smokers. Since we observed that subject smoking status impacted NER 
efficiency via an interaction effect with subject age, we concluded that the 
smoking distribution needs to be comparable between groups.  As such, we 
compared the NER efficiency of the current smoking case subjects to the current 
smokers in the control group (Figure 7.3).  In the youngest age group, the case 
subjects had a significantly slower NER efficiency than the youngest current 
smoking control subjects.  However, the sample sizes in this limited analysis are 
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quite small, only 7 cases and 7 controls.  A larger study that includes greater 
representation of individuals under the age of 50 would be desired to obtain a 
more meaningful comparison between cases and controls using this repair 
assay.  Separating the study participants by age group and smoking status is not 
typically done in population studies evaluating DNA repair as a biomarker of 
cancer risk, and although these results are from smaller than desired sample 
sizes, they suggest that both smoking status and age play a role in individual 
NER efficiency.  Since we have observed a reduction in NER efficiency with 
increasing subject age among the control population, but not the case population, 
this assay may most informative in case-control studies on younger individuals.  
As cancer is a disease of aging, detecting cancer risk early is a very useful 
preventative tool. 
Ultimately, the goal of measuring DNA repair, be it by measuring 
polymorphisms in DNA repair genes, by measuring levels of proteins involved in 
DNA repair, or with an assay to determine individual DNA repair efficiency, is to 
use this measurement as a biomarker of cancer susceptibility in a healthy 
population.  As stated above, there have been considerable efforts to use the 
association of repair gene polymorphisms and cancer incidence as a predictor for 
cancer risk.  The drawback to these sorts of studies is that genetic 
polymorphisms do not tell the whole story – they cannot provide a measure of 
how efficiently the expressed proteins would interact in a repair process that 
requires the concerted efforts of dozens of individual factors.  Measuring protein 
levels also has this limitation.  While there may be statistically significant 
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associations between the levels of various proteins involved in DNA repair and 
cancer risk, it is also possible that an individual who has normal levels of the 
measured proteins has a deficiency elsewhere that increases cancer risk.  The 
best way to capture the whole picture of an individual’s cancer risk is to perform a 
functional assay to measure the ability of their DNA repair machinery to remove 
DNA damage.  We have successfully implemented a functional assay to 
measure NER efficiency in a human population, and from that study we have 
discovered insights into the factors that modulate NER efficiency.  Primary 
among these factors is subject age, and related to that is that observation that 
smoking interacts with subject age to regulate NER efficiency. 
Previous studies have observed an age effect on DNA repair (albeit TC-
NER via the host-cell reactivation assay) in isolated lymphocytes, and there has 
been some evidence that smoking status may affect repair as well, but the 
interplay between these two factors has not, to our knowledge, been observed 
before.  We found that non-smokers, who were (mostly) cancer free in our study, 
did not show an age dependent reduction in NER efficiency, while current and 
former smokers did (Table 7.1).  This was a rather unexpected finding, since the 
total study population (n = 198) and the control only population (n = 156) each 
show a significant reduction in NER efficiency with increasing subject age.  In 
other words, the smoking population, which represented about half of the control 
subjects and over half of the total subject population, had such a strong age-
dependent reduction in NER efficiency that it effectively masked the lack of an 
age-dependent response in the non-smokers.  Additionally, the total female 
164 
 
population did not have a significant age-dependent decline in NER efficiency, 
but the control female population did.  This was a result of the female case 
subjects who did not have an age-dependent reduction in NER efficiency and 
therefore masked the age-dependent reduction in NER efficiency in the control 
female population when they were grouped together in the “total female” 
population.  These findings highlight the importance of determining not only what 
factors effect NER efficiency in a population before a comparison between cases 
and controls can be done, but additionally the findings suggest that variables can 
interact with each other to contribute to the distribution of NER efficiency within a 
population and that these interactions must also be properly understood and 
corrected for when measuring NER efficiency in a case/control study as a marker 
of cancer susceptibility in a population.  
7.4 The relationship between metal exposure and NER efficiency in a 
human population 
 Our investigation of the levels of NER efficiency in an at-risk population in 
Appalachian Kentucky, a population where lung cancer rates are greater than 
expected based on smoking prevalence, also included collecting environmental 
exposure data.  Of principle interest was the potential exposure to arsenic, an 
established human lung carcinogen, and the relationship between any exposure 
and NER efficiency.  Since we had observed that arsenic, in an acute, high 
concentration exposure, could reduce NER efficiency in multiple cell culture 
models, we hypothesized that arsenic exposure in a human population could also 
result in a reduction in NER efficiency.  A U.S. study found that individuals with 
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toe-nail arsenic levels above a certain threshold (0.114 µg arsenic/1 gram nail) 
had a significant association with small-cell and squamous-cell carcinoma of the 
lung compared with those in the lowest exposure group [83].  A previous study 
indicated that residents of Appalachian Kentucky had significantly higher toenail 
arsenic levels than a non-Appalachian reference county, with over a quarter of all 
samples exceeding the 0.114 µg/g threshold [321]. We ran a similar comparison, 
looking at lung cancer risk in the highest exposed population compared to the 
lowest exposure group, and determined that there was no appreciable increase 
in cancer incidence (odds ratio ).  The arsenic exposure levels in the reference 
study were considerably higher than those seen in the Appalachian Kentucky 
study, which may make meaningful comparisons based on arsenic nail levels 
difficult.  About 22% of the nail samples in the reference study, across cases and 
controls, had arsenic nail levels above the threshold indicated above.  In our 
study, only 11% of the subjects whose lymphocytes were analyzed for repair had 
toenail arsenic levels above the same threshold.  Even though the levels of 
arsenic in the nails were low, we also investigated the relationship between 
arsenic nail levels and the efficiency of NER (Fig 7.4 A).  We found no trend in 
half-life values with increasing arsenic concentrations in subject toenails.  In 
general, toenail metal analysis revealed that there was little exposure to toxic 
metals such as arsenic, cadmium, lead, and nickel (data not shown).  These low 
levels, while certainly a positive for the individuals in the region, make any 
analysis of the effects of heavy metal exposure difficult.  We therefore shifted 
focus to look at the effect of essential trace metals, such as selenium, 
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manganese, chromium and iron, on the efficiency of NER for any potential 
protective effects.  Although we saw no relationship between chromium and 
selenium levels in toenails and NER efficiency, we observed a positive 
correlation between the efficiency of NER and toenail concentrations of both 
manganese and iron in a statistically significant manner (Fig 7.4 B/C).  Iron is an 
essential cofactor for all three mammalian DNA polymerases and is required by 
the NER factor XPD to facilitate its helicase activities [322].  Manganese is used 
by SOD2 to reduce oxidative damage in the mitochondria, where the superoxide 
radical is generated during mitochondrial respiration.  Oxidation of NER factors 
has been implicated as a mechanism through which oxidative damage may 
inhibit NER [323].  It follows then that, within the non-toxic range of 
concentrations of these two metals, higher levels of iron and manganese could 
promote DNA repair, and indeed we observed an increase in the efficiency of 
NER with increasing toenail concentrations of manganese and iron.  We then 
chose to examine the relationship between the efficiency of NER and nail metal 
exposure between individuals who had the highest exposure of a given metal to 
the remainder of the population (Table 7.2).  When comparing the toenail 
samples containing the highest concentrations of manganese or iron 
(approximately top 10%) to the remainder of the samples, the high metal level 
groups had a greater DNA repair rate (reduced half-life) compared to the 
remainder of the study population (Fig 7.5 A/B).  In the case of manganese, the 
difference was statistically significant.  When subjects were grouped based on 
their toenail arsenic levels, on the other hand, there was no difference in NER 
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efficiency between the two groups (Fig 7.5 C).  In this case, the cutoff used was 
close to the level (0.114 µg As/g nail) that produced a significant risk for 
developing certain lung cancers [83]. 
7.5 Future directions 
 The NER pathway is vital to the prevention of DNA mutations that drive 
carcinogenesis.  The efficiency of the pathway fluctuates within a population, 
both as a consequence of an age-dependent decline in NER efficiency as well as 
the existence of many polymorphisms in the genes involved in NER.  Additional 
environmental factors may also contribute to variations in NER efficiency.  Less 
efficient NER faculties could result in increased mutational burdens, and 
individuals who are subject to higher levels of DNA damage (like smokers) would 
be at an even higher risk of developing cancer should their NER efficiency be 
low.  It is this premise that has drawn us into investigating the NER pathway as 
potential biomarker for cancer susceptibility.  Our efforts exploring the causes for 
increased lung cancer incidence in Appalachian Kentucky produced mixed 
results.  Overall, there was no reduction in NER efficiency in the lung cancer 
subjects compared to the control subjects.  After observing that these two 
populations showed very different responses to increasing subject age as it 
related to NER efficiency, and after concluding that smoking had a dramatic 
effect on the observed age-dependent decline in NER efficiency, we determined 
that both smoking and age must be controlled for when performing a case-control 
study using our measurement of NER efficiency.  Unfortunately, correcting for 
age and smoking status reduced the sample size of the only population that 
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showed any substantial difference in NER efficiency between cases and controls, 
young smokers.   
 In addition to the hypothesis that reduced NER efficiency could increase 
lung cancer risk in the Appalachian Kentucky population, there were two 
additional hypotheses that were developed after cell culture work determined that 
environmental factors, namely tobacco smoke (condensate) and arsenic, could 
inhibit the efficiency of NER.  We hypothesed that (1) tobacco smoke or (2) 
arsenic could cause a reduction in the NER efficiency of individuals within the 
study population who were exposed to these environmental agents.  This then 
extends the hypothesis that reduced NER efficiency could increase cancer risk to 
include a possible explanation as to how the NER efficiency of individuals could 
be reduced.  As this was the first time the repair assay was used to measure 
NER efficiency in a human population, there is no external reference point to 
compare the measures to, and it is therefore impossible to determine if 
individuals in Appalachia as a whole have reduced NER efficiency compared to 
those outside the region.  Further studies are required to compare NER efficiency 
measured in this study to populations outside the region.  Rather, the study 
permitted comparisons of NER efficiency between lung cancer cases and 
controls, as well as between individuals who were and were not exposed to 
various environmental agents.  The results of the comparison of half-lives 
between cases and controls has been laid out above.  The impact of tobacco 
smoke on NER efficiency was not what was expected.  As detailed in chapter 6, 
the different smoking populations did not have statistically different average half-
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lives, after adjusting for the difference in ages between the populations.  The cell 
culture work suggested that tobacco smoke could potentially inhibit NER 
efficiency, and as such a hypothesis was established that posited that smokers in 
Appalachia would have a reduced NER efficiency as a consequence of their 
smoking.  Instead, the current and former smokers had faster rates of repair 
relative to the non-smoking population, although the difference was not 
significant, and was likely highly influenced by the disparity in average ages of 
the smoking populations (See Table 6.1).  The other hypothesis cultivated by the 
cell culture studies that applied to the human population study on NER efficiency 
was related to arsenic exposure.  Arsenic, in cultured skin and lung cells, 
reduced NER efficiency.  It was hypothesized that this would occur in the human 
population study, that individuals exposed to arsenic would have reduced NER 
efficiency.  This was tied to an additional hypothesis that arsenic levels in the 
region were sufficiently high to increase lung cancer incidence in exposed 
individuals.   
Neither of these turned out to be the case.  Arsenic levels were quite low 
in the nail samples from individuals in the Appalachian study, and there was no 
correlation between arsenic levels and either cancer incidence or NER efficiency.  
Given the low level of exposure, it would not be prudent to conclude that arsenic 
is not a risk factor for lung cancer development, but rather that this population 
lacked sufficient exposure to arsenic to observe any affect it might have on lung 
cancer risk.  The same can be said for the impact of arsenic exposure on NER 
efficiency.  There is no comparable study that investigated NER efficiency as it 
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correlates to arsenic exposure in a human population, so the conclusion that 
arsenic levels were insufficiently high to perform a comparison with NER 
efficiency will have to remain based on the fact that arsenic levels were not high 
enough to increase lung cancer risk.   
Rather than try to draw conclusions regarding the impact of heavy metal 
exposure on NER efficiency when exposure was quite low, another opportunity 
presented itself within the metal data collected.  Essential trace metal exposure 
data was also collected, and there were sufficient levels of several of these 
metals to examine their relationship to NER efficiency.  As indicated in section 
7.4, manganese and iron showed a positive relationship with NER efficiency in a 
statistically significant manner.  While it was not part of the hypothesis relating to 
lung cancer incidence in the region, the positive association between NER 
efficiency and manganese and iron levels provides evidence that this measure of 
NER efficiency can be correlated to environmental exposures.  The positive 
association between essential trace metals and NER efficiency may pave the 
way for further studies of the relationship between NER efficiency and metal 
exposure in individuals who have higher levels of exposure to toxic metals like 
arsenic, cadmium, nickel, and lead.   
Ultimately, NER efficiency may be a useful tool in predicting cancer risk, 
especially among individuals who are already at increased risk due to factors like 
smoking or excessive sun exposure.  The repair assay discussed herein needs 
to be validated in a large case-control study with appropriate matching 
conditions.  Age, smoking status, and perhaps even gender should all be 
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considered when establishing a case-control study that measures NER efficiency 
as an indicator of cancer risk.  As cancer is a disease of aging, and since cases 
and controls showed dramatically different age-dependent changes in NER 
efficiency, measuring NER efficiency using the technique described herein would 
like be most effective in a younger population.  As it is designed to provide a 
measure of cancer risk, those individuals with poor NER efficiency would be able 
to take that knowledge and perhaps decide to mitigate their risk by reducing 
exposure to DNA damaging agents such as sunlight and tobacco smoke.  
Knowing you are at a high risk for developing cancer may be the incentive 
needed to make a lifestyle change, avoiding additional risk factors, which will 
reduce the risk of developing cancer.  
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Table 7.1 The effect of subject age on NER efficiency in different 
populations of the study 
 
Table 7.1 Subject age was plotted against half-life for each individual in a given 
population and a linear regression analysis was performed.  The R2 value and 
subsequent P-value derived from the R2 value are shown in Table 7.1 for the 
total, control, and case populations as well as further divisions within each of 
these groups.
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Table 7.2 Half-life values of individuals in high metal exposure populations 
compared to the remainder of the population 
 
Table 7.2 Individuals who had toenail levels of arsenic, manganese, or iron 
above cutoffs representing approximately the 90th percentile for each metal we 
compared to those below the cutoff for each metal.  The sample size, half-lives, 
and standard deviation are shown for each population, along with a p-value from 
a 2-way Student’s T-test comparing the half-lives of individuals above and below 
the cutoff for each metal are shown. 
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Figure 7.1 NER efficiency is not affected by subject age in lung cancer 
subjects
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Figure 7.1 Scatter plots of the distribution of half-lives compared to subject age 
is shown for (A) the total lung cancer population, (B) the current smokers with 
lung cancer, (C) the former smokers with lung cancer, (D) the male subjects with 
lung cancer, and (E) the female subjects with lung cancer. All populations show 
no significant reduction in NER efficiency with increasing subject age.  
Regression analysis of the scatter plots provided R2 values of 0.0496, 0.0025, 
0.0256, 0.0650, and 0.0002 for the total, current smoking, forming smoking, 
male, and female populations, respectively.  The associated p-values were all 
non-significant (see table 7.1). 
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Figure 7.2 NER efficiency in cases verses controls separated by age group 
Figure 7.2  (A) A graph of the mean +/- standard error for half-life in each age 
group separated by case and control subjects.  (B) A table of the results shown in 
(A).  When comparing the cases to control at each age group, the controls have 
a greater NER efficiency in the youngest age group (although not significantly), 
while they have a reduced NER efficiency in the middle and oldest age groups 
compared to the cases. 
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Figure 7.3 NER efficiency in current smoking cases verses controls 
separated by age group 
 
Figure 7.3  (A) A graph of the mean +/- standard error for half-life of current 
smokers in each age group separated by case and control subjects.  (B) A table 
of the results shown in (A).  When comparing the cases to control at each age 
group, the controls have a greater NER efficiency in the youngest age group (p = 
0.0307), while they have a lower NER efficiency in the middle and oldest age 
groups compared to the cases (p = 0.1689 and 0.0316 for middle and oldest age 
groups, respectively). 
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Figure 7.4 The relationship between NER efficiency and toenail metal 
concentration in a human population 
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Figure 7.4 (A) A scatter plot of the half-life vs toenail arsenic levels shows no 
correlation.  A linear regression analysis of the data produced an R2 value of 
0.0012 (p = 0.667).  (B) A scatter plot of the half-life vs toenail manganese levels 
shows a reduction in half-life with increasing manganese concentration.  A linear 
regression analysis of the data produced an R2  value of 0.0265 (p = 0.045). (C) 
A scatter plot of the half-life vs toenail iron levels shows a reduction in half-life 
with increasing iron concentration.  A linear regression analysis of the data 
produced an R2  value of 0.0333 (p = 0.026).  
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Figure 7.5 NER efficiency of individuals in the study population separated 
into high and low metal exposure for Mn, Fe, and As 
  
181 
 
Figure 7.5 (A) A graph of the average half-life and standard error from 
individuals above and below 1 µg Manganese / 1 g toenail is shown. (B) A graph 
of the average half-life and standard error from individuals above and below 30 
µg Iron / 1 g toenail is shown. (C) A graph of the average half-life and standard 
error from individuals above and below 0.125 µg Arsenic/ 1 g toenail is shown.  
These cutoffs roughly separate the population into a 10% high exposure 
population and the remaining 90% of the population for each metal exposure. 
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